3rd Inflammatory Skin Disease Summit
The Translational Revolution
December 12-15, 2018
Aula der Wissenschaften, Vienna, Austria

FINAL PROGRAM
Provided by the Austrian Academy of Sciences

www.isds2018.org
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>WELCOMING WORDS</td>
<td>2</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>3</td>
</tr>
<tr>
<td>CONGRESS VENUE</td>
<td>4</td>
</tr>
<tr>
<td>REGISTRATION</td>
<td>8</td>
</tr>
<tr>
<td>NETWORKING EVENTS</td>
<td>9</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAM INFORMATION</td>
<td>10</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAM</td>
<td>14</td>
</tr>
<tr>
<td>ACCEPTED ABSTRACTS</td>
<td>22</td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SESSIONS</td>
<td>52</td>
</tr>
<tr>
<td>SPONSORS &amp; EXHIBITORS</td>
<td>61</td>
</tr>
</tbody>
</table>
Welcoming Words

Over the last few decades, biomedical research has unraveled a plethora of pathophysiological steps putatively important for human disease development. But it was only in the last few years that a broader translation from basic research efforts to clinical medicine has indeed occurred. This was largely made possible by the close cooperation of basic researchers and clinical investigators, aiming at the development of truly effective therapeutics. Inflammatory skin diseases such as psoriasis and atopic dermatitis serve as an example of this successful bench-to-bedside approach. Currently, more and more therapies are approved as a result of this scientific approach, and many more are on their way.

Nevertheless, a stand-alone meeting in which inflammatory skin diseases and the translational revolution that we are currently experiencing take center stage has been lacking. After two very successful meetings in Vienna in 2014 and in New York City in 2016, we have again taken upon the task of organizing such an important meeting in order to continue this path of therapeutic revolution and extend to other inflammatory skin diseases. We want to discuss new concepts and new developments in the field of inflammatory skin diseases and to devise and explore new therapeutic strategies.

We want to thank all participants who have decided to join us for what we hope will be a scientifically most stimulating event, all invited speakers and poster presenters for sharing their work with us, our generous sponsors, and all the helping hands making this meeting possible. We would also like to thank the Austrian Academy of Sciences for her patronage.

We very much hope that you will enjoy this symposium in the heart of Vienna!

With kind regards,

Emma Guttman-Yassky, MD, PhD
James G. Krueger, MD, PhD
Georg Stingl, MD
Patrick M. Brunner, MD, MSc
General Information

ORGANIZING COMMITTEE

Emma Guttman-Yassky, MD, PhD
Professor and Vice-Chair
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY, USA

James G. Krueger, MD, PhD
Director
Milstein Medical Research Program
Senior Attending Physician
D. Martin Carter Professor in Clinical Investigation
Laboratory for Investigative Dermatology
The Rockefeller University
New York, NY, USA

Georg Stingl, MD
Professor
Department of Dermatology
Medical University of Vienna
Vienna, Austria

Patrick M. Brunner, MD, MSc
Associate Professor
Department of Dermatology
Medical University of Vienna
Vienna, Austria

General Organization

SCIENTIFIC SECRETARIAT, REGISTRATION, HOTEL AND SPONSORSHIP
INCL. COMMERCIAL EXHIBITION

Mondial Congress & Events
Operngasse 20b
1040 Vienna, Austria
Phone: +43 1 58804 – 0
Email: isds2018@mondial-congress.com
Congress Venue

Aula der Wissenschaften
Wollzeile 27a
A-1010 Vienna, Austria
www.aula-wien.at/en

How to get to the Meeting

PUBLIC TRANSPORTATION
Public transport in Vienna is very well developed, clean and safe and moreover the fastest way of commuting in the city center. Therefore we recommend to go by underground or tram.

- Underground U3 – Station ‘Stubentor’ (3 min)
- Underground U1 or U3 – Station ‘Stephansplatz’ (7 min)
- Underground U1 or U4 – Station ‘Schwedenplatz’ (7 min)
- Tram no. 2 – Station ‘Stubentor’ (3 min)

More information about public transport on www.wienerlinien.at.

PARKING
Since parking near the congress venue is generally short-term, it is highly advisable to use a public parking garage in the area.

- Garage Cobdengasse
  Cobdengasse 2
  1010 Vienna

- Georg Cochplatz Tiefgarage
  Georg Cochplatz 4
  1010 Vienna

- Parkhaus City
  Stephansplatz/Schulerstraße
  1010 Vienna
Congress Venue

GROUND FLOOR

Entrance Bäckerstraße 20  
(open only Wed., Dec. 12, 2018)

First Floor

Entrance Wollzeile 27a

Poster & Catering Area  
Exhibition

Poster Area  
Coat Room

Registration
Congress Venue

SECOND FLOOR

Lecture Hall 'Jesuitensaal'

Speaker's Lounge
Registration

The registration area is located in the entry hall on the ground floor. The meeting staff will be pleased to help you with any inquiries. Please do not hesitate to approach the team members if there is anything they can do to make your stay more enjoyable.

REGISTRATION DESK HOURS

— Wednesday, December 12, 2018 14:00 – 19:00
— Thursday, December 13, 2018 08:00 – 17:30
— Friday, December 14, 2018 08:00 – 17:30
— Saturday, December 15, 2018 07:30 – 14:30

ONSITE REGISTRATION FEES

<table>
<thead>
<tr>
<th>Registration Fee</th>
<th>€ 550</th>
</tr>
</thead>
<tbody>
<tr>
<td>Students* / Residents &amp; Fellows**</td>
<td>€ 300</td>
</tr>
</tbody>
</table>

* Student Fee: Students need to provide a copy of their valid Student ID when registering; otherwise student registration will not be accepted.

** Residents/Fellows: In order to verify your status, written confirmation from your hospital/ institution is required, otherwise regular admission will apply.

THE REGISTRATION FEE INCLUDES:

— Participation in the scientific program (incl. industry sessions)
— Congress materials (bag, final program, name badge)
— Food & Beverages during congress opening hours
— Attendance at Welcome Reception & Poster Viewing on Wednesday, December 12, 2018
— Admission to the exhibition area

PAYMENT DETAILS

Please note that all onsite payments need to be made by credit card (Visa, MasterCard, American Express, Diners will be accepted) or in cash in Euro (€) only. We cannot accept traveller’s checks, other credit cards, Euro checks or other currencies.

CME ACCREDITATION

The 3rd Inflammatory Skin Disease Summit has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Official Networking Events & Catering during the Conference

WELCOME RECEPTION & POSTER VIEWING
Date and Time: Wednesday, December 12, 2018 | 18:30 – 21:00
Location: Congress Venue - Aula der Wissenschaften,
Poster Areas (Ground Floor & First Floor)

OFFICIAL NETWORKING EVENING
Date and Time: Thursday, December 13, 2018 | 19:00
Location: Augustinerkeller
Augustinerstraße 1, 1010 Vienna

Admission to the Official Networking Evening is € 30 per person.
Tickets for this event need to be purchased beforehand via our website, or at the registration desk at the conference site.
The Augustinerkeller can be reached from the conference venue in just a 15 minute stroll through the city center. No bus transfer will be provided.

BREAKFAST, COFFEE BREAKS AND LUNCH
Will be provided in the morning, during the respective breaks and in industry supported symposia.
The official catering area is located on the first floor.
Scientific Program Information

OPENING HOURS – SPEAKERS’ LOUNGE
The Speakers’ Lounge is located on the second floor, next to the lecture hall. The hours of operation are as follows:

- Wednesday, December 12, 2018  14:00 – 18:30
- Thursday, December 13, 2018  07:30 – 17:30
- Friday, December 14, 2018  07:30 – 18:00
- Saturday, December 15, 2018  07:00 – 13:30

PRESENTATION GUIDELINES
1. Speakers are required to provide their USB drives containing their PowerPoint presentation to the AV technician in the Speaker’s Lounge on the second floor at least two hours prior to the start of the respective session. For sessions starting in the morning, the PowerPoint should be delivered the previous day. We strongly encourage you not to bring your own laptop. Presentation should be on USB.
2. Please locate the session prior to your presentation time and be there at least 15 minutes before the start of the session.
3. Speakers can view/check their PowerPoint presentations at the Speakers’ Lounge

SESSION CHAIR GUIDELINES
Please locate the session room in due time and be there at least 15 minutes prior to the start of the session. Please make sure that speakers strictly stick to the time schedule.

POSTERS
The poster areas are located on two floors. Each poster will be displayed for the entire duration of the summit. Posters have to be mounted on Wednesday, December 12, 2018 before 16:00. Please attach the poster to the board with the corresponding poster placement number and remove it on Saturday, December 15, 2018 until 14:30.

ABSTRACT BOOK
A printed abstract book will be provided in your congress bag. Moreover, the abstracts will be published in ‘Experimental Dermatology’.

TRAVEL FELLOWSHIPS
Travel Fellowships are paid in cash in EUR and need to be picked up personally at the registration desk.
Invited Speakers

Masayuki Amagai, MD, PhD
Professor
Department of Dermatology
Keio University
Tokyo, Japan

Thomas Bieber, MD, PhD, MDRA
Professor and Chair
Department of Dermatology and Allergy
University Hospital Bonn
Bonn, Germany

Bruce Bochner, MD
Professor
Northwestern University Feinberg School of Medicine
Chicago, IL, United States

Patrick Brunner, MD, MSc
Associate Professor
Medical University of Vienna
Vienna, Austria

Jean-Laurent Casanova, MD, PhD
Professor
The Rockefeller University
New York, NY, United States

Rachael Clark, MD, PhD
Associate Professor
Brigham & Women’s Hospital, Harvard Medical School
Boston, MA, United States

Christophe Dupont, MD, PhD
Professor
Hôpital Necker-Enfants malades
Dept. of Pediatric Gastroenterology, Hepatology and Nutrition
Université Paris Descartes
Paris, France

Massimo Gadina, MD, PhD
Director
Office of Science and Technology
NIH/National Institute of Arthritis, Musculoskeletal & Skin Diseases
Bethesda, MD, United States

Richard Gallo, MD, PhD
Professor and Chair
Department of Dermatology
University Of California
San Diego, CA, United States

Joel Gelfand, MD, MSCE
Professor
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA, United States

Michel Gilliet, MD
Professor and Chair
Department of Dermatology
Lausanne University Hospital (CHUV)
Lausanne, Switzerland

Emma Guttman-Yassky, MD, PhD
Professor and Vice-Chair
Departement of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY, United States

John Harris, MD, PhD
Associate Professor
Dpt. of Medicine,
Dermatology Division
University of Massachusetts Medical School
Worcester, MA, United States
Alan Irvine, MD, DSc  
Professor  
Trinity College Dublin  
Dublin, Ireland

Kenji Kabashima, MD, PhD  
Professor and Chair  
Department of Dermatology  
Kyoto University  
Kyoto, Japan

James Krueger, MD, PhD  
Professor  
Laboratory for Investigative Dermatology  
The Rockefeller University  
New York, NY, United States

Vijay Kumar Kuchroo, MD, DVM, PhD  
Professor  
Brigham & Women’s Hospital,  
Harvard Medical School  
Boston, MA, United States

Thomas Kupper, MD  
Head of the Department of Dermatology  
Brigham & Women’s Hospital, Harvard Medical School  
Boston, MA, United States

Graham Ogg, MD  
Professor  
MRC Human Immunology Unit Oxford University Hospitals NHS Foundation Trust  
Oxford, United Kingdom

Amy S. Paller, MD  
Professor and Chair  
Department of Dermatology  
Northwestern University  
Feinberg School of Medicine  
Chicago, IL, United States

Virginia Pascual, MD  
Director  
Drukier Institute for Children’s Health at Weill Cornell Medicine  
New York, NY, United States

Ralf Paus, MD  
Professor  
Division of Musculoskeletal & Dermatological Sciences  
The University of Manchester  
Manchester, United Kingdom

Kristian Reich, MD  
Professor  
Director JeruCON GmbH  
Hamburg, Germany

Eli Sprecher, MD, PhD  
Professor and Director  
Department of Dermatology  
Tel Aviv Sourasky Medical Center  
Tel Aviv, Israel

Martin Steinhoff, MD  
Professor  
Department of Dermatology and Venerology  
Hamad Medical Corporation  
Medical School  
Qatar University  
Doha, Qatar

Georg Stingl, MD  
Professor  
Department of Dermatology  
Medical University of Vienna  
Vienna, Austria

Ruth Ann Vleugels, MD, MPH  
Associate Professor  
Harvard Medical School  
Boston, MA, United States
SESSION CHAIRS

Tove Agner (Copenhagen, Denmark)
Daniel Aletaha (Vienna, Austria)
Matthias Augustin (Hamburg, Germany)
Zuhair Ballas (Iowa City, IA, USA)
Robert Bissonnette (Montreal, Canada)
Patrick M. Brunner (Vienna, Austria)
Michael Detmar (Zurich, Switzerland)
Adelheid Elbe-Bürger (Vienna, Austria)
James T. Elder (Ann Arbor, Michigan, USA)
Stefanie Eyerich (Munich, Germany)
Amos Gilhar (Haifa, Israel)
Emma Guttman-Yassky (New York, NY, USA)
DirkJan Hijnen (Rotterdam, Netherlands)
Alain Hovnanian (Paris, France)
Sylvia Knapp (Vienna, Austria)
Donald Leung (Denver, CO, USA)
Thomas Luger (Münster, Germany)
Luis Puig (Barcelona, Spain)
Matthias Schmuth (Innsbruck, Austria)
Erwin Tschachler (Vienna, Austria)
Stephan Weidinger (Kiel, Germany)
Peter Wolf (Graz, Austria)

ORAL ABSTRACT PRESENTERS

Daphne Bakker (Utrecht, Netherlands)
Anna Berekmeri (Leeds, United Kingdom)
Robert Bissonnette (Montreal, Canada)
Ian M. Catlett (Princeton, NJ, USA)
Tali Czarnowicki (New York, NY, USA)
Ester Del Duca (New York, NY, USA)
Liv Eidsmo (Stockholm, Sweden)
Seth Forman (Tampa, FL, USA)
Mayumi Fujita (Aurora, CO, USA)
Johann Gudjonsson (Ann Arbor, MI, USA)
Emma Guttman-Yassky (New York, NY, USA)
Moayed Hamza (Dublin, Ireland)
Richard Langley (Halifax, Canada)
Tomoko Maeda-Chubachi (Morrisville, NC, USA)
Brian Nickoloff (Indianapolis, IN, USA)
Johanna Strobi (Vienna, Austria)
Anna Tallman (New York, NY, USA)
Claudia Traidl-Hoffmann (Augsburg, Germany)
Marc Vocanson (Lyon, France)
Nicole Ward (Cleveland, OH, USA)
Christina Zielinski (Munich, Germany)
Scientific Program

WEDNESDAY, DECEMBER 12, 2018

14.00  REGISTRATION OPENS

Opening
Chairs:  Emma Guttman-Yassky (New York, NY, USA),
         Patrick M. Brunner (Vienna, Austria)

16.00 – 16.10  Welcome address
16.10 – 16.35  Setting the stage – Historic perspectives
               Georg Stingl (Vienna, Austria)
16.35 – 17.00  Setting the stage – The translational revolution in inflammatory
               skin diseases
               James G. Krueger (New York, NY, USA)
17.00 – 17.30  Two sides of Th17 cells in autoimmunity and tissue homeostasis
               Vijay Kuchroo (Boston, MA, USA)
17.30 – 18.30  Oral presentations from selected abstracts
Chairs:  Erwin Tschachler (Vienna, Austria), Luis Puig (Barcelona, Spain)

#125: Selective oral JAK3 and TYK2/JAK1 kinase inhibitors both
demonstrate significant hair-growth compared to placebo and
improvement of hair-associated keratins in patients with moderate-to-severe Alopecia Areata
Emma Guttman-Yassky (New York, NY, USA)

#130: A selective inhibitor of TYK2, BMS-986165, improves
molecular, cellular, and clinical biomarkers associated with
efficacy in moderate-to-severe psoriasis
Ian M. Catlett (Princeton, NJ, USA)

#86: A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in
patients with moderate-to-severe plaque psoriasis
Seth Forman (Tampa, FL, USA)
#123: New innovative approach combining comparative transcriptomics from three unique psoriasis models to identify predictive PsA biomarkers  
Johann Gudjonsson (Ann Arbor, MI, USA)

#LB 4 Guselkumab demonstrates superior long-term responses to secukinumab at Week48 in the treatment of moderate to severe psoriasis: Results from the ECLIPSE trial  
Richard Langley (Halifax, Canada)

18.30 - 21.00  
Poster viewing and networking

THURSDAY, DECEMBER 13, 2018

08.00 - 08.30  
REGISTRATION & BREAKFAST

Morning lectures  
Chairs: Sylvia Knapp (Vienna, Austria), Michael Detmar (Zurich, Switzerland)

08.30 - 09.00  
A perspective of dendritic cells in inflammatory skin diseases  
Thomas Bieber (Bonn, Germany)

09.00 - 09.30  
Resident T cells in health and disease  
Rachael Clark (Boston, MA, USA)

09.30 - 10.00  
T cell subsets across inflammation and cancer  
Thomas S. Kupper (Boston, MA, USA)

10.00 - 10.30  
Innate lymphoid cells in health and disease  
Graham Ogg (Oxford, United Kingdom)

10.30 - 10.45  
Oral presentations from selected abstracts  
#112 Resident T cells trigger disease-associated tissue responses that stratify clinical outcome in human psoriasis  
Liv Eidsmo (Stockholm, Sweden)

10.45 - 11.00  
BREAK

11.00 - 12.30  
Lunch symposium  
Supported by Eli Lilly (see page 52)

12.30 - 13.00  
BREAK
Afternoon lectures

Chairs: Donald Leung (Denver, CO, USA), Stefanie Eyerich (Munich, Germany)

13.00 – 14.00 Oral presentations from selected abstracts

#138 Blood endotyping distinguishes the profile of vitiligo from other inflammatory and autoimmune skin diseases
Tali Czarnowicki (New York, NY, USA)

#102 Low-input RNA sequencing reveals survival program of human skin-resident T cells during complete myeloablation
Johanna Strobl (Vienna, Austria)

#78 A critical role for IL-37 in regulatory T cell maintenance and CD4+ T cell inhibition
Mayumi Fujita (Aurora, CO, USA)

#70 KLK6-PAR1 signaling drives psoriasiform manifestations in skin and bone and blockade of PAR1 in explanted psoriasis patient skin decreases key psoriasis transcripts
Nicole Ward (Cleveland, OH, USA)

14.00 – 14.30 Protective immunity and immunodeficiencies
Jean-Laurent Casanova (New York, NY, USA)

14.30 – 15.00 Genetics of inflammatory skin diseases
Eli Sprecher (Tel Aviv, Israel)

15.00 – 15.30 COFFEE BREAK

Chairs: DirkJan Hijnen (Rotterdam, The Netherlands), Adelheid Elbe-Bürger (Vienna, Austria)

15.30 – 16.00 Janus kinases in inflammation
Massimo Gadina (Bethesda, MD, USA) on behalf of John O’Shea (Bethesda, MD, USA)

16.00 – 16.30 Visualization of skin inflammation and resulting immunologic concepts
Kenji Kabashima (Kyoto, Japan)

16.30 – 17.00 The microbiome and therapeutic implications
Richard Gallo (San Diego, CA, USA)
17.00 - 17.30 Oral presentations from selected abstracts

#74 Triple correlation between skin microbiome, skin barrier and immune gene expression pathways in atopic dermatitis
Claudia Traidl-Hoffmann (Augsburg, Germany)

#45 Baseline inflammatory biomarker profiles and clinical heterogeneity of adult patients with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids
Brian Nickoloff (Indianapolis, IN, USA)

19.00 Official Networking Evening (Augustinerkeller)
FRIDAY, DECEMBER 14, 2018

08.00 - 08.30 REGISTRATION & BREAKFAST

08.30 - 09.30 Breakfast symposium
Supported by Janssen (see page 53)

09.30 - 09.45 BREAK

Morning lectures
Chairs: Stephan Weidinger (Kiel, Germany), James T. Elder (Ann Arbor, MI, USA)

09.45 - 10.15 How to perform successful clinical trials in inflammatory skin diseases
Kristian Reich (Hamburg, Germany)

10.15 - 10.45 Framing psoriasis
James G. Krueger (New York, NY, USA)

10.45 - 11.15 Autoantigens in psoriasis
Michel Gilliet (Lausanne, Switzerland)

Joel Gelfand (Philadelphia, PA, USA)

11.45 - 12.00 BREAK

12.00 - 13.30 Lunch symposium
Supported by Pfizer (see page 56)

13.30 - 13.45 BREAK

Afternoon lectures
Chairs: Matthias Schmuth (Innsbruck, Austria), Zuhair Ballas (Iowa City, IA, USA)

13.45 - 14.15 Inflammatory profile of atopic dermatitis and cytokine targeted treatments
Emma Guttman-Yassky (New York, NY, USA)

14.15 - 14.45 Barrier defects in atopic dermatitis and prevention strategies
Alan Irvine (Dublin, Ireland)

14.45 - 15.15 Atopic dermatitis at disease onset
Patrick M. Brunner (Vienna, Austria)
15.15 - 15.45  Adopting Orphan Ichthyoses: New Focus for Inflammatory Skin Research
Amy S. Paller (Chicago, IL, USA)

15.45 - 16.15  COFFEE BREAK
Chairs: Alain Hovnanian (Paris, France), Tove Agner (Copenhagen, Denmark)

16.15 - 16.45  Epicutaneous antigen desensitization
Christophe Dupont (Paris, France)

16.45 - 17.15  Peripheral tolerance to autoimmune target in pemphigus
Masayuki Amagai (Tokyo, Japan)

17.15 - 18.05  Oral presentations from selected abstracts

#48 Conjunctival inflammation and loss of goblet cells in atopic dermatitis patients treated with dupilumab in daily practice
Daphne Bakker (Utrecht, Netherlands)

#90 Proteomics analysis shows that non-invasive epidermal sampling is a robust diagnostic approach for inflammatory skin diseases
Anna Berekmeri (Leeds, United Kingdom)

#67 Major differences in expression of inflammatory products in skin from different body sites of healthy individuals
Ester Del Duca (New York, NY, USA)

#21 Sodium chloride is an ionic checkpoint for human Th2 cell responses and shapes the atopic skin microenvironment
Christina Zielinski (Munich, Germany)
SATURDAY, DECEMBER 15, 2018

07.30 - 08.00  REGISTRATION & BREAKFAST

08.00 - 09.30  Breakfast symposium
Supported by Sanofi Genzyme (see page 57)

09.30 - 09.45  BREAK

Morning lectures
Chairs:  Amos Gilhar (Haifa, Israel), Thomas Luger (Münster, Germany)

09.45 - 10.00  Oral presentations from selected abstracts
#120 Massive expansion of drug-specific, clonotypic and polyclonal cytotoxic CD8+ T cells in Toxic Epidermal Necrolysis
Marc Vocanson (Lyon, France)

10.00 - 10.30  Alopecia areata
Ralf Paus (Manchester, UK)

10.30 - 11.00  Acne & Rosacea
Martin Steinhoff (Dublin, Ireland)

11.00 - 11.30  Vitiligo
John Harris (Worcester, MA, USA)

11.30 - 12.00  LUNCH BREAK

Afternoon lectures
Chairs:  Peter Wolf (Graz, Austria), Daniel Aletaha (Vienna, Austria)

12.00 - 12.30  Eosinophilic disorders
Bruce Bochner (Chicago, IL, USA)

12.30 - 13.00  Adding new pieces to the old Lupus puzzle
Virginia Pascual (New York, NY, USA)

13.00 - 13.30  Dermatomyositis
Ruth Ann Vleugels (Boston, MA, USA)
Chairs: Robert Bissonnette (Montreal, Canada), Matthias Augustin (Hamburg, Germany)

13.30 – 14.20 Oral presentations from selected abstracts

#117 Early Improvement in Pruritus and Reduction in Clinical Signs in a Phase 2a Mechanism of Action Study of Crisaborole in Mild to Moderate Atopic Dermatitis
Robert Bissonnette (Montreal, Canada)

#30 A Topical Nitric Oxide-Releasing Cream SB414: Results of a Phase 1b Double-Blind, Randomized, Vehicle-Controlled Study in Patients with Mild-to-Moderate Atopic Dermatitis
Tomoko Maeda-Chubachi (Morrisville, NC, USA)

#88 Topical DS107 for the treatment of mild-to-moderate Atopic Dermatitis: Results from ADVANTAGE, an 8 week phase 2b randomized, double-blind, vehicle-controlled study
Moayed Hamza (Dublin, Ireland)

#103 Cerdulatinib (DMVT-502), a novel, topical dual Janus kinase/spleen tyrosine kinase inhibitor, improves the cellular and molecular cutaneous signature in patients with atopic dermatitis
Anna Tallman (New York, NY, USA)

14.20 – 14.30 Closing session
Accepted Abstracts

All abstracts will be published in ‘Experimental Dermatology’ (see printed abstract book in your meeting bag).

1. Apoptosis regulating proteins: bcl-2, p53 and caspase-3 expression in psoriasis
   Debdeep Mitra
   
   1Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India

2. Cytokine gene polymorphisms and their relation with NFκB Expression and Histopathological Features in Psoriasis
   Debdeep Mitra
   
   1Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India

3. Interleukin 31 gene expression in laboratory controlled mast cells under the influence of Interleukin 33 and Interleukin 4: Clinical implication in patients with atopic dermatitis
   Barnali Mitra
   
   1Department of Pediatrics, Base Hospital Delhi Cantt, New Delhi, India

4. Double-Blind, Placebo- Controlled, Randomized Study Comparing 0.0003% Calcitriol ointment with 1% Pimecrolimus cream for the Treatment of Pityriasis Alba
   Debdeep Mitra
   
   1Department of Dermatology Base Hospital Delhi Cantt, New Delhi, India

5. A Randomized Controlled Trial of Anti-TNF alpha Bio-similar Adalimumab versus Prednisolone in the Management of Leprosy Patients with New Type 1 Lepra Reaction
   Debdeep Mitra
   
   1Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India

6. A randomized, double-blind, placebo-controlled study of monoclonal Anti-IgE antibody Omalizumab in the management of pruritus in chronic spontaneous urticaria in the pediatric population
   Barnali Mitra
   
   1Department of Pediatrics, Base Hospital Delhi Cantt, New Delhi, India
Development of a multi-gene expression profile for recurrence risk prediction in cutaneous squamous cell carcinoma
Aaron Farberg1, Ashley Wysong2, Jason Newman3, Kyle Covington4, Kristen Plasseraud4, Robert Cook4, Chrysalyne Schmults5, Sarah Arron6
1Icahn School of Medicine At Mount Sinai, New York, USA, 2University of Nebraska, Omaha, USA, 3University of Pennsylvania Health System, Philadelphia, USA, 4Castle Biosciences, Inc., Friendswood, USA, 5Brigham and Women's Hospital, Boston, USA, 6University of California San Francisco, San Francisco, USA

Sweet’s Syndrome Presenting as Disseminated Herpes Zoster
Ellie Choi1, Chris Tan1
1National University Hospital, Singapore, Singapore

HY209 ameliorates atopic dermatitis by attenuating TSLP expression in mice
Youn-Hee Kim3,4,5, Aziz Ghaderpour1,2, Hai-Chon Lee1, Bong Jik Kim1, Hyunmi Park1, Hae Jung Kim1, Hyun-Woo Kim1, Min-Jeong Yi1, Sung Su Kim1, Seung-Yong Seong1,2,3,4,5
1Wide River Institute of Immunology, Seoul National University, Hongcheon, South Korea, 2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea, 3Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, South Korea, 4Clinical Research Institute, Seoul National University Hospital, Seoul, South Korea, 5Shaperon co., Seoul, South Korea

Comorbidity of pustular psoriasis and bullous pemphigoid: a case report and review of the literature
Christine Brägelmann1, Dennis Niebel1, Jörg Wenzel1, Thomas Bieber1
1Clinic and Policlinic for Dermatology and Allergology, University of Bonn, Germany

Extracts of Mimosine Free Plant Cell Culture (Mimosa Pudica sp.) Exhibit Anti-Inflammatory Activities And Inhibit Th2 Responses In Vitro
Christine Libon1, Nicolas Steward1, Eng Adrien Cousy1, Jérôme Rouquet1, Claire Issac1, Antonio Grondin, Martine Maitre1, Yves Brunel1, Alain Latil1, Thien Nguyen1
1Pierre Fabre Research Institute, Toulouse, France

Lupus and Leprosy “The Great Imitator”
Ahmed Abd-Elbary1, Shaimaa Shoela
1Alexandria Faculty Of Medicine, Alexandria, Egypt
13 Neutrophils contribute to vasculitis by increased release of Neutrophil Extracellular Traps in Behçet’s Disease
Rémi Safi1, Romy Kallas2, Tara Bardawil3, Carl Joe Mehanna4, Ossama Abbas3, Rola Hamam4, Imad Uthman2, Abdul-Ghani Kibbi3, Dany Nassar1,3,5
1 Department of Anatomy, Cell Biology and Physiological Science, American University of Beirut, Beirut, Lebanon, Beirut, Lebanon, 2Division of Rheumatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Beirut, Lebanon, 3Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon, Beirut, Lebanon, 4Division of Ophthalmology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon, Beirut, Lebanon, 5Hôpital Cochin Tarnier, Département de Dermatologie, Université Paris Descartes, Paris, France, Paris, France

14 Targeting the Jak-STAT pathway in the treatment of recalcitrant cutaneous granulomatous disorders
William Damsky1, Durga Thakral1, Nkiruka Emeagwali2, Anjela Galan1, Brett King1
1 Yale Department Of Dermatology, New Haven, United States, 2Yale Department of Internal Medicine, New Haven, United States

15 Oxygen therapy of inflammatory skin diseases
Jeonghae Kie2, Juyoung Seoh3
2 Ewha Womans University, Seoul, South Korea, 3National Health Insurance Cooperation Ilsan Hospital, Koyang, South Korea

16 Temporomandibular joint (TMJ) arthritis in psoriasis
Ellie Choi1, Chris Tan
1 National University Hospital, Singapore, Singapore

17 Efficacy and Safety of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis over 24 Weeks: Results from a Phase 2 Trial
Philip J. Mease1, Herbert Kellner2, Akimichi Morita3, Alan J. Kivitz4, Kim A. Papp5, Stella Aslanyan6, Beate Berner, Su Chen8, Ann Eldred9, Frank Behrens10
18 Efficacy and Safety of Risankizumab (RZB) Compared with Adalimumab (ADA) in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the Phase 3 IMMvent Trial
Kristian Reich1, Melinda Gooderham2, Diamant Thaçi3, Jeffrey J. Crowley4, Caitriona Ryan5, James G. Krueger6, Tsai7, Mary Flack8, Yihua Gu9, David A. Williams9, Elizabeth H. Z. Thompson10, Carle Paul11
1 SCIderm Research Institute Hamburg, and Dermatologikum, Berlin, Germany, 2 Queen’s University, Kingston, ON and Centre for Dermatology and Probiotic Medical Research, Peterborough, Canada, 3 Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 4 Bakersfield Dermatology, Bakersfield, United States, 5 University College, Dublin, Ireland, 6 The Rockefeller University, New York, United States, 7 National Taiwan University College of Medicine, Taipei, Taiwan, 8 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States, 9 AbbVie Inc., North Chicago, United States, 10 AbbVie Inc, Redwood City, United States, 11 Paul Sabatier University and Larrey Hospital, Toulouse, France

19 Characterization of the Psoriasis-like Inflammation in the Imiquimod Rat Model using the clinical method of Dermal Open Flow Microperfusion
Manfred Bodenlenz1, Thomas Birngruber1, Barbara Prietl2, Kyriakos Economides3, Peter Florian3, Arun Subramaniam1, Thomas Hultsch1, Reingard Raml1, Anita Eberl1, Selma Mautner1, Frank Sinner1,2
1 HEALTH - Institute for Biomedicine and Health Sciences, Joanneum Research ForschungsgembH, Graz, Austria, 2 Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria, 3 Immunology and Inflammation TA, Cambridge, MA, USA and Frankfurt, Germany

20 PF-04965842, a JAK1 Inhibitor, Modulates Pharmacodynamic and Disease Biomarkers in Blood of Atopic Dermatitis Patients
Elizabeth Kieras1, Weidong Zhang1, Christopher Banfield1, Jean Beebe1, Michael Vincent1, Elena Peeva1
1 Pfizer Inc., Cambridge, United States

21 Sodium chloride is an ionic checkpoint for human Th2 cell responses and shapes the atopic skin microenvironment
Julia Matthias, Hanna Meinl, Ying-Yin Chao, Heiko Gerstenberg, Christina Zielinski1
1 Technical University of Munich, Munich, Germany, 2 German Center for Infection Research, Munich, Germany

22 Safety and efficacy of alitretinoin in elderly patients with moderate to severe chronic hand eczema
Mihn-Sook Jue1, Mingyul Jo1
1 Department of Dermatology, Veterans Health Service Medical Center, Seoul, South Korea
23 **Skin microbiome limits UV-induced immune suppression by inducing expression of pro-inflammatory genes and increases neutrophilic infiltration in the skin**

Vijay Kumar Patra1,2,3, Karin Wagner1, Velmurugesan Arulampalam3, Peter Wolf2

1 Center for Medical Research, Medical University of Graz, Graz, Austria, 2 Research Unit for Photodermatology, Department of Dermatology, Medical University of Graz, Graz, Austria, 3 Core Facility for Germfree Research (CFGR), Department of Comparative Medicine and Department of Microbiology, Tumor, and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden

24 **Keratinocytes are the primary target of dithranol in psoriasis**

Theresa Benezeder1, Clemens Painsi2, Vijaykumar Patra1, Ulrike Schmidbauer1, Bernhard Lange-Asschenfeld2, Peter Wolf1

1 Department of Dermatology, Medical University Of Graz, Graz, Austria, 2 Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria

25 **Papuloerythroderma of Ofugi: A case report and review of existing literature, disease associations, diagnosis and definition as a single disease entity**

Laura Hui1, PoYin Tang2, ShiuMing Pang1

1 Department of Dermatology, Singapore General Hospital, Singapore, Singapore, 2 Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore

26 **Pharmacological validation of models relevant to acne with topical retinoids**

Amadeu Gavaldà1, Ana Blanco1, Eric Lacoste2, Virginie Albinet2, Nuria Godessart1

1 Almirall R&D Centre, Barcelona, Spain, 2 Imavita S.A.S., Toulouse, France

27 **A preclinical model for studying herpes simplex virus infection**

Poojabahen Taipara1, Michael Mildner2, Ralf Schmidt3, Martin Vierhapper4, Johannes Matiasek6, Theresia Popow-Kraupp3, Christopher Schuster5, Adelheid Elbe-Bürger6

1, Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden, 2, Department of Dermatology, Research Division of Biology and Pathobiology of the Skin, Medical University of Vienna, Austria, 3 Department of Laboratory Medicine, Division of Clinical Virology, Medical University of Vienna, Austria, 4 Department of Surgery, Division of Plastic and Reconstructive Surgery, Medical University of Vienna, Austria, 5 Department of Plastic, Aesthetic and Reconstructive Surgery, St. Josef Hospital, Austria, 6 Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Austria

28 **Establishment of a pig model of delayed wound healing using human wound exudate**

Barbara Wolff-Winiski1, Hermann Fahrngruber1, Petra Dörfler1, Nicole Schöfmann1, Anton Stütz3

1 Akribes Biomedical GmbH, Vienna, Austria
29 Assessing the role of MMP14 in the pathogenesis of acne vulgaris using sebocyte organoid models
Kenneth Fong1, Khek Chian Tham2, Pei Wen Lee2, Hazel Oon3, Xin Hong Lim2, Maurice van Steensel2
1 National Skin Centre, Singapore, Singapore, 2 Institute of Medical Biology, A*STAR, Singapore, Singapore

30 A Topical Nitric Oxide-Releasing Cream SB414: Results of a Phase 1b Double-Blind, Randomized, Vehicle-Controlled Study in Patients with Mild-to-Moderate Atopic Dermatitis
Tomoko Maeda-Chubachi1, Todd Durham1, Stephen Schleicher2, Phoebe Rich3, Emma Guttman-Yassky4
1 Novan, Inc, Morrisville, NC, United States, 2 Dermdox, Hazleton, United States, 3 Oregon Dermatology and Research Center, Portland, United States, 4 Icahn School of Medicine at Mount Sinai Medical Center, New York, United States

31 Stimulating T cell Inhibitory Receptor VISTA for the Treatment of Cutaneous Lupus
Matthew Vesely1, Xue Han1, Miguel Sanmamed1, Ti Badri1, Lieping Chen1
1 Yale University, New Haven, United States

32 Subcutaneous white adipose tissue - an immunological compartment underlying the skin?
Marie-Charlotte Brüggen1, Johanna Strobl2, Nick Li3, Frieder Koszik2, Reiko Naito3, Maximilian Zaida4, Hajnal Kiprov5, Lars French1, Georg Stingl1
1 Department Of Dermatology, University Hospital Zurich, Zurich, Switzerland, 2 Dpt of Dermatology, Medical University of Vienna, Vienna, Austria, 3 Dpt of Dermatology, Fukuoka University Faculty of Medicine, Fukuoka, Japan, 4 Dpt of Internal Medicine III, Div of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria, 5 Private Hospital Kiprov, Vienna, Austria

33 Ex vivo culture of psoriasis skin for pharmacological testing
Minna Tiirikainen1, Hanne Norsgaard2, Anders Woetmann2, Paola Lovato1
1 LEO Pharma A/S, Ballerup, Denmark, 2 University of Copenhagen, Copenhagen, Denmark

34 The immune response modifier imiquimod is metabolized by AHR-dependent cytochrome P450 enzymes: Implications for psoriasis research
Melina Mescher1, Julia Tigges1, Jean Krutmann1, Dieter Lang2, Thomas Haarmann-Stemmann1
1 Leibniz-Research Institute for Environmental Medicine, Düsseldorf, Germany, 2 Bayer AG, Drug Discovery, Wuppertal, Germany
35 Interaction between mucosal and cutaneous immune responses to Streptococcus pyogenes in psoriasis: a role for antigen specific IgA and CLA+ T cells
Carmen De Jesús-Gil1, Marta Ferran2, Anca Chiriac3, Antonio Celada4, Ramon M. Pujol2, Luis F Santamaria-Babí1
1 Translational Immunology (PCB), University of Barcelona, Barcelona, Spain, 2Dept of Dermatology, Hospital del Mar, IMIM, Univ Autónoma de Barcelona, Barcelona, Spain, 3Dept of Dermatophysicsiology, Apollonia University, Iasi, Romania, 4Macrophage Biology. Univ of Barcelona, Barcelona, Spain

36 Acne and stress: impact of catecholamines on Cutibacterium acnes
Valérie Borrel1, Pauline Thomas1, Yoan Konto-Ghiorghi1, Luc Lefeuvre2, Cécile Duclairoir-Poc1, Marc Feuilloley1
1 University of Rouen, Laboratory of Microbiology Signals and Microenvironment, Evreux, France, 2R&D Uriage Dermatologic Laboratory, Neuilly sur Seine, France

37 Reduced IL-22 responsiveness in chronic discoid lupus erythematosus lesion
Adewonuola Alase1, Yuzailf Yusof1, Mark Goodfield2, Martin Stacey3, Edward Vital1, Miriam Wittmann1
1 Leeds Institute of Rheumatic And Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, 2Department of Dermatology, Chapel Allerton Hospital, Leeds Teaching Hospital Trust, Leeds, United Kingdom, 3School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom

38 Effects of a selective JAK1 inhibitor on MC903- and TSLP-induced skin inflammation in mice
Zhi Su1, Stephanie Paulsboe1, Joseph Wetter1, Katherine Salte1, Maria Namovic1, Laura Leys1, Yibing Wang1, Prisca Honore1, Steve McGaraughty1
1 AbbVie Inc. (Parent), North Chicago, United States

39 Dandruff/seborrheic dermatitis: impact of the use of an anti-dandruff shampoo relayed by a rebalancing shampoo on dandruff states and microbiota communities of the scalp
Marie Favennec, Eleonore Gravier2, Virginie Turlier2, Sandie Le Guédard-Méreuze1, Marie, Florence Galliano, Valérie Mengeaud3, Sandrine Bessou-Touya3, Nathalie Casterix-Rizzi1
1 Research And Development Pierre Fabre Center, Toulouse, France, 2Clinical Skin Research and Development Pierre Fabre Center, Toulouse, France, 3Ducray Laboratories, Lavour, France
12/15-lipoxygenase counteracts and resolves pemphigoid disease-like dermatitis
Tanya Sezin¹, Nerea Ferreirós², Detlef Zillikens¹, Gerd Geißlinger², Christian Sadik¹
¹University Of Lübeck, Lübeck, Germany, ²pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

SERPINB2 and miR-146a/b coordinately suppress psoriasis-associated inflammatory responses in human keratinocytes
Helen Vaher¹, Anet Kivihall¹, Toomas Runnel¹, Liisi Raam²,³, Ele Prans¹,², Kristi Abram³, Bret Kaldvee²,³, Ulrich Mrowietz⁴, Stephan Weidinger⁴, Külli Kingo²,³, Ana Rebane¹
¹Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia, ²Department of Dermatology and Venereology, University of Tartu, Tartu, Estonia, ³Dermatology Clinic, Tartu University Hospital, Tartu, Estonia, ⁴Department of Dermatology, University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany

The effects of skin psoriasis inflammation on adipose tissue-derived mediators and viceversa
Roberta Di Caprio¹, Anna Balato², Giuseppina Ciaiazzo¹, Emanuele Scala¹, Annunziata Raimondi¹, Marco Romanelli³, Andrea Chiricozzi³
¹Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, ²Institute of Protein Biochemistry, National Research Council, Naples, Italy, ³Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy, ⁴Department of Dermatology, University of Pisa, Pisa, Italy

Th-17 and antimicrobial peptides in HS: is there a link?
Emanuele Scala¹, Roberta Di Caprio¹, Sara Cacciapuoti¹, Giuseppina Ciaiazzo¹, Donatella De Pascale², Giovanna Donnarumma³, Alessandra Fusco³, Emiliana Tortorella², Gabriella Fabbrocini¹, Anna Balato⁴
¹Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, ²Institute of Protein Biochemistry, National Research Council, Naples, Italy, ³Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, ⁴Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy

The keratinocyte transcriptome in psoriasis: pathways related to immune responses, cell cycle and keratinization
Lorenzo Pasquali¹, Ankit Srivastava¹, Florian Meisgen¹, Kunal Das Mahapatra¹, Ping Xia¹,³, Ning Xu Landén¹, Andor Pivarcsí, Eniko Sonkoly¹,²
¹Dermatology and Venereology Section, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Dermatology Unit, Karolinska University Hospital, Stockholm, Sweden, ³Dermatology Unit, Wuhan N.1 Hospital, Wuhan, China
Baseline inflammatory biomarker profiles and clinical heterogeneity of adult patients with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids
Jonathan Sims1, Ching-Yun Chang1, Richard Higgs1, Eric Simpson2, Jonathan Silverberg3, Seth Forman4, Jonathan Janes5, Fabio Nunes5, Brian Nickoloff5, Emma Guttman-Yassky5
1 Eli Lilly and Company, Indianapolis, United States, 2Department of Dermatology, Oregon Health & Science University, Portland, United States, 3Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago, United States, 4Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at the Mount Sinai Medical Center, New York, United States

Pediatric Study in Atopic Dermatitis (PEDISTAD): A Prospective, Observational, Longitudinal Study in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
Amy Paller1, Emma Guttman-Yassky2, Alan Irvine3, Eulalia Baselga4, Marjolein de Bruin-Weller5, Shyamalie Jayawardena6, Paola Mina-Orsorio7, Zafer Ozturk8
1 Northwestern University Feinberg School Of Medicine, Chicago, United States, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Trinity College Dublin, Dublin, Ireland, 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 5University Medical Center Utrecht, Utrecht, Netherlands, 6Sanofi, Bridgewater, USA, 7Regeneron Pharmaceuticals, Inc., 8Sanofi Genzyme, Cambridge, USA

RNA-seq Genomic Analysis Demonstrated the Molecular Efficacy of Risankizumab in a Moderate-to-Severe Plaque Psoriasis Phase 2 Clinical Study
T Pakozdi1, RW Georgantas1, KM Grebe2, S Viswanathan3, P Baum4, Wade Davis1
1 Genomics Research Center of Excellence, AbbVie Inc., North Chicago, United States, 2AbbVie Bioresearch Center, AbbVie Inc., North Chicago, United States, 3Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States, 4Boehringer Ingelheim Pharma GmbH & Co., KG, Germany

Conjunctival inflammation and loss of goblet cells in atopic dermatitis patients treated with dupilumab in daily practice
Daphne Bakker1, Lieneke Ariëns1, Chantal van Luijk2, Deepak Balak1, Jorien van der Schaft1, Judith Thijs1, Marie-Louise Schuttelaar3, Robbert Wisse2, Edward Knol1,4, Leo Koenderman4,5, Yvonne Vercoulen4, Marijke van Dijk5, Femke van Wijk4, Marjolein de Bruin-Weller1
1 National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands, 2Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands, 3Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands, 4Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the
WITHDRAWN

ASNO02, a dual oral inhibitor of JAK/SYK signaling, improves the lesional skin phenotype towards non-involved skin in moderate-to-severe atopic dermatitis patients, correlating with clinical outcomes

Emma Guttman-Yassky², Ana Pavel², Teresa Song², Hyun Je Kim³, Robert Bissonnette³, Louis Denis¹, Niranjan Rao³, David Zammit¹
¹Asana Biosciences, Lawrenceville, United States, ²Icahn School of Medicine at Mount Sinai, New York, USA, ³Innovaderm Research, Montreal, Canada

A review of cutaneous adverse reactions induced by immune checkpoint inhibitors

Vijaya T. Daniel¹,², Mehdi Rashighi²
¹Department of Dermatology, University of Massachusetts Medical School, Worcester, United States, ²Department of Surgery, University of Massachusetts Medical School, Worcester, United States

PASH Treated Successfully with Infliximab

Shashendra Aponso¹, Karen Choo¹, Haur Yueh Lee¹
¹Department of Dermatology, Singapore General Hospital, Singapore

11ß-hydroxysteroid dehydrogenase 1 expression in the skin could be related with atopic dermatitis

Beom Jun Kim¹, Noo Ri Lee¹, Hyun Jee Hwang¹, Eunjung Kim¹, Eung Ho Choi¹
¹Department of Dermatology, Wonju, South Korea

Secondary Kinetoprophylaxis in Psoriatic Arthropathy

Virgil Patrascu¹, Lavinia Claudia Ochiana¹, Florentina Delcea¹, Octavian Alexe²
¹UMF Craiova, Craiova, Romania, ²Universitatea Dunarea de Jos, Galati, Romania

Expression of MMP-1 gene in localized sklerodermia

Vladimir Sobolev¹,², Anna Soboleva³, Zofiya Nevozinskaya³, Nikolay Potekaev³, Anastas Piruzyan³, Eugeniya Dvoryankova¹, Irina Korsunskaya¹,³
¹Centre Of Theoretical Problems Of Physico-chemical Pharmacology, Moscow, Russian Federation, ²I.I. Mechnikov Research Institute for Vaccines and Sera RAMS, Moscow, Russian Federation, ³Moscow Scientific Practical Center of Dermatovenereology and Cosmetology, Moscow, Russian Federation
56 The influence of glycyrrhizinic acid on the expression of pro-inflammatory cytokins in psoriatic skin
Anna Soboleva1, Vladimir Sobolev1,2, Eugeniya Dvoryankova1, Kristina Plieva4, Malika Denieva3, Irina Korsunskaya1,4
1Centre Of Theoretical Problems Of Physico-chemical Pharmacology, Moscow, Russian Federation, 2I.I. Mechnikov Research Institute for Vaccines and Sera RAMS, Moscow, Russian Federation, 3Chechen State University, Grozny, Russian Federation, 4Moscow Scientific Practical Center of Dermatovenereology and Cosmetology, Moscow, Russian Federation

57 Dupilumab improves outcomes of concurrent asthma and atopic dermatitis—pooled analysis of four phase 3 studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)
Jonathan Corren1, Andrew Blauvelt2, Thomas Hultsch3, Ana B. Rossi3, Elena Rizova3, Laurent Eckert4, Abhijit Gadkari5, Yufang Lu4, Brad Shumel5, Heribert Staudinger6, Zhen Chen6, Marius Ardeleanu5
1David Geffen School of Medicine at UCLA, Los Angeles, USA, 2Oregon Medical Research Center, Portland, USA, 3Sanofi Genzyme, Cambridge, USA, 4Sanofi, Chilly-Mazarin, France, 5Regeneron Pharmaceuticals, Inc., Tarrytown, USA, 6Sanofi, Bridgewater, USA

58 Dupilumab improves outcomes of concurrent chronic sino-nasal conditions and atopic dermatitis—pooled analysis of four phase 3 studies (LIBERTY AD SOLO 1&2, CHRONOS, and CAFÉ)
Margitta Worm1, Weily Soong2, Thomas Hultsch, Ana B. Rossi3, Laurent Eckert4, Abhijit Gadkari5, Brad Shumel5, Zhen Chen5, Marius Ardeleanu5
1Department of Dermatology and Allergology, Charité-Universitätsmedizin, Berlin, Germany, 2Alabama Allergy and Asthma Center, Birmingham, USA, 3Sanofi Genzyme, Cambridge, USA, 4Sanofi, Chilly-Mazarin, France, 5Regeneron Pharmaceuticals, Inc., Tarrytown, USA

59 UHPLC-MS/MS quantitative profiling of eicosanoids in diluted interstitial fluid samples from a rat model of psoriasis-like skin inflammation
Reingard Raml1, Cornelia Pipper1,2, Natalie Bordag2, Berndette Reiter1, Kyriakos Economides3, Peter Florian4, Thomas Birngruber1, Frank Sinner1, Manfred Bodenlenz2, Anita Eberl1
1Joanneum Research, Institute for Biomedicine and Health Sciences, Bioanalytics and Metabolomics, Graz, Austria, 2CBmed, Center for Biomarker Research in Medicine, Graz, Austria, 3Sanofi, Immunology & Inflammation Research TA, Type 2 Inflammation & Fibrosis, Framingham, USA, 4Sanofi, Immunology & Inflammation Research TA, Type 1/17 Immunology and Arthritis Cluster, Industriepark Höchst, Frankfurt am Main, Germany
60 Costimulatory blockade with abatacept did not prevent psoriasis relapse after discontinuation of ustekinumab: Results of a clinical trial
Dawn Smilek¹, Robert Bissonnette², Kirk Barber³, Erin Boh⁴, Steven Feldman⁵, Gerald Krueger⁶, Yolanda Helfrich⁷, Neil Korman⁸, Anne Laumann⁹, Howard Sofen¹⁰, James McNamara¹¹, Margie Byron¹², Kristina Harris¹³, James Krueger¹⁴
¹Immune Tolerance Network, University of California San Francisco, San Francisco, United States, ²Innovederm Research Inc., Montreal, Canada, ³University of Calgary, Calgary, Canada, ⁴Tulane University School of Medicine, New Orleans, USA, ⁵Wake Forest School of Medicine, Department of Dermatology, Winston-Salem, USA, ⁶University of Utah, Department of Dermatology, Salt Lake City, USA, ⁷University of Michigan, Department of Dermatology, Ann Arbor, USA, ⁸University Hospitals Cleveland Medical Center, Cleveland, USA, ⁹Feinberg School of Medicine, Northwestern University, Chicago, USA, ¹⁰David Geffen UCLA School of Medicine, Los Angeles, USA, ¹¹Division of Allergy, Immunology and Transplantation, NIAID, NIH, Rockville, USA, ¹²Rho, Inc., Chapel Hill, USA, ¹³Immune Tolerance Network, Bethesda, USA, ¹⁴The Rockefeller University, New York, USA

61 CD23 is a biomarker of clinical response to IgE-specific immunoadsorption in patients with severe atopic eczema
Jenny Thomas¹, Rosi Wang², Richa Batra³, Fabian J. Theis⁴, Stefanie Eyerich¹, Alex Zink², Kilian Eyerich²
¹ZAUM - Center of Allergy and Environment, Member of Technical University of Munich and Helmholtz Center Munich, Munich, Germany, ²Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany, ³Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany, ⁴Department of Mathematics, Technical University of Munich, Garching, Germany

62 Next generation sequencing identifies the keratinocyte-specific miRNA signature of psoriasis
Ankit Srivastava¹, Florian Meisgen¹, Lorenzo Pasquali¹, Sara Munkhammar¹, Ping Xia³, Mona Ståhle², Ning Xu Landén¹, Andor Pivarcsi¹, Enikő Sónkoly²
¹Dermatology and Venerology Section, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Unit of Dermatology, Karolinska University Hospital, Stockholm, Sweden, ³Unit of Dermatology, Wuhan No.1 Hospital, Wuhan, China

63 Sebaceous lipogenesis of human sebocytes is suppressed by nicotinic acid via the activation of hydroxycarboxylic acid receptor 2 (HCA2)
Arnold Markovics¹, Kinga Fanni Tóth¹, Katalin Eszter Sós¹², József Magi¹, Adrienn Gyöngyösi³, Zoltán Benyö⁴, Christos C. Zouboulis⁵, Tamás Biró⁶⁷, Attila Oláh¹
¹Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ²Laboratory of Cerebral Cortex Research, Institute of Experimental Medicine Hungarian Academy of Sciences, Budapest, Hungary, ³Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ⁴Institute of Clinical Experimental
Role of Galectin-1 in contact hypersensitivity
Raquel Castillo-González, Danay Cibrian, Nieves Fernández-Gallego, Marta Ramírez-Huesca, Hortensia de la Fuente, Francisco Sánchez-Madrid
1 Fundación De Investigación Biomédica HUP, Madrid, Spain, 2 Universidad Autónoma de Madrid, Madrid, Spain, 3 Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain

LAT1 controls expansion and IL-17 release by Vδ4+ and CD4 T cells in psoriasis
Danay Cibrian, Raquel Castillo-González, Nieves Fernández-Gallego, Maria Laura Saiz, Hortensia de la Fuente, Carmen Punzón, Marta Ramírez, Manuel Fresno, Esteban Daudén, Julián Aragonés, Francisco Sánchez-Madrid
1 Fundación de Investigación Biomédica HUP, Madrid, España, 2 Universidad Autónoma de Madrid, Madrid, España, 3 Centro de Biología Molecular Severo Ochoa, Madrid, España

Inhibition of STAT5 with IQDMA reduces cell viability in cutaneous T cell lymphoma cells in-vitro and decreases tumor growth in a lymphoma animal model
Saptaswa Dey, Pablo Augusto Vieyra-Garcia, Lukas Kenner, Olaf Merkel, Peter Wolf
1 Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria, 2 Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria

Major differences in expression of inflammatory products in skin from different body sites of healthy individuals
Ester Del Duca, Ana B. Pavel, Celina Dubin, Teresa Song, Elizabeth Brezinski Wallace, Xiangyu Peng, Yeriel D. Estrada, Hui Xu, Catherine Maari, Carolyn Jack, Etienne Saint-Cyr Proulx, James G. Krueger, Robert Bissonnette, Emma Guttman-Yassky
1 Department of Dermatology and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA, 2 Department of Dermatology, University of Colorado, Aurora, USA, 3 Innovaderm Research Inc, Montreal, Canada, 4 Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA
68 Evaluating influence of baseline characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a Phase 2 trial
Kenneth Gordon1, Kim Papp2, Melinda Gooderham3, Diamant Thaçi4, Peter Foley5, Akimichi Morita6, Sudeep Kundu7, Renata Kisa7, Andrew Napoli7, Subhashis Banerjee7
1Medical College of Wisconsin, Milwaukee, United States, 2K Papp Clinical Research and Probity Medical Research, Waterloo, Canada, 3SKiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, Canada, 4University of Luebeck, Luebeck, Germany, 5The University of Melbourne, St Vincent’s Hospital Melbourne & Probity Medical Research, Skin & Cancer Foundation Inc, Melbourne, Australia, 6Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 7Bristol-Myers Squibb, Princeton, United States

69 Rapid and effective itch relief from calcipotriol plus betamethasone dipropionate foam in patients with psoriasis
A Jalili1, M Lebwohl2, LS Gold3, SB Andersen4, KL Jensen4, D Thaçi5
1Department of Dermatology, Bürgenstock Medical Center, Obbürgen, Switzerland, 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA, 3Henry Ford Health System, Detroit, USA, 4LEO Pharma, Ballerup, Denmark, 5Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany

70 KLK6-PAR1 signaling drives psoriasiform manifestations in skin and bone and blockade of PAR1 in explanted psoriasis patient skin decreases key psoriasis transcripts
Jessica Ludwig1, Dennis Gruszka1, Yi Fritz2, Richard Rozic2, William Swindell3,4, Ranjith Uppala1, Mrinal Sarkar1, Ronald Midura2, Johanna Gudjonsson4, Nicole Ward1
1Case Western Reserve University, Cleveland, United States, 2Cleveland Clinic Foundation, Cleveland, United States, 3Ohio University, Athens, United States, 4University of Michigan, Ann Arbor, United States

71 Understanding the role of JNK1 in the the context of skin inflammation
Aurore Le1, Assiya Assabban1, Nicolas Istaces1, Iain Welsby1, Séverine Thomas1, Muriel Nguyen1, Thomas Wunderlicht2, Jens Bruning2, Laurye Van Maele1, Stanislas Goriely1
1Institute of Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium, 2Institute for Genetics, University of Cologne, Cologne, Germany

72 Rapid onset of action with topical fixed-dose combination calcipotriol plus betamethasone dipropionate cutaneous foam in patients with psoriasis, irrespective of baseline disease severity
A Pink1, M Torpet2, KL Jensen2, S Segaert3
1St John's Institute of Dermatology, Guy's and St Thomas’ NHS Foundation Trust, London, United Kingdom, 2LEO Pharma A/S, Ballerup, Denmark, 3Consultant Dermatologist, Leuven, Belgium
Influence of baseline demographics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis: a Phase 2, randomized, placebo-controlled trial

Melinda Gooderham1, Kim Papp2, Kenneth Gordon3, Peter Foley4, Akimichi Morita5, Diamant Thaçi6, Sudeep Kundu7, Renata Kisa7, Andrew Napoli7, Subhashis Banerjee7

1SKiN Centre for Dermatology, Queen's University and Probiity Medical Research, Peterborough, Canada, 2K Papp Clinical Research and Probiity Medical Research, Waterloo, Canada, 3Medical College of Wisconsin, Milwaukee, United States, 4The University of Melbourne, St Vincent’s Hospital Melbourne & Probiity Medical Research, Skin & Cancer Foundation Inc, Melbourne, Australia, 5Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 6University of Luebeck, Luebeck, Germany, 7Bristol-Myers Squibb, Princeton, United States

Triple correlation between skin microbiome, skin barrier and immune gene expression pathways in atopic dermatitis

Claudia Traidl-Hoffmann1, Thomas Nussbaumer1, Matthias Reiger1, Can Altunbulakli2, Cezmi Akdis2, Avidan Neumann1

1Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Zentrum München, Augsburg, Germany, Augsburg, Germany, 2Swiss Institute for Allergy and Asthma Research, University of Zurich, Davos, Switzerland, Davos, Switzerland

IL-17C and IL17A promote skin inflammation in a tiered manner using IL-17RE, IL-17RA and IL-17RC

Antia Veal1, Jessica Ludwig1, Dennis Gruszka1, Sigrun Sigurdardottir1, Yi Fritz1, Philip Klenotic1, Nicole Ward1

1Case Western Reserve University, Cleveland, United States

etermines the type of inflammation in psoriasis mice model

Hidetoshi Tsuda1, Mayumi Komine1, Tomoyuki Hioki1, Susume Nakae2, Mamitaro Ohtsuki1

1Jichi Medical University, Shimotsuke, Japan, 2The Institute of Medical Science The University of Tokyo, Minato-ku, Japan

Dupilumab Therapy for Chronic Refractory Hand Dermatitis

Thy Huynh1, Suhail Hadi2, Kathryn Tan2, Emma Gutman-Yassky2

1Univ. Of Mississippi Medical Center, Jackson, United States, 2Icahn School of Medicine at Mount Sinai, New York, United States
78 A critical role for IL-37 in regulatory T cell maintenance and CD4+ T cell inhibition
Douglas Grant Osborne1, Joanne Domenico2, Charles A Dinarello2,3, Mayumi Fujita1,2,4
1University Of Colorado SOM, Dermatology, Aurora, United States, 2University of Colorado SOM, Immunology & Microbiology, Aurora, United States, 3University of Colorado SOM, Medicine, Aurora, United States, 4Dept of VA, Eastern Colorado Health Care System, Aurora, United States

79 Apremilast did not affect normal human epidermal keratinocytes
Meijuan Jin1, Mayumi Komine1, Hidetoshi Tsuda1, Mamitaro Ohtsuki1
1Jichi Medical University, Department of Dermatology, Tochigi, Japan

80 Open Flow Microperfusion (OFM) samples unfiltered and undiluted interstitial fluid from skin
Joanna Adamczak1, Reingard Raml1, Frank Sinner1, Thomas Birngruber1
1Joanneum Research - HEALTH Institute, Graz, Austria

81 Cases with higher IL-33 expression in lesional epidermal keratinocytes show better response to TNF inhibitors
Tomoyuki Hioki2, Mayumi Komine1, Meijuan Jin1, Hidetoshi Tsuda1, Mamitaro Ohtsuki1
1Jichi Medical University, Shimotsuke, Japan, 2Kizawa Memorial Hospital, Minokamo, Japan

82 First experience of dupilumab in atopic dermatitis patients treated in daily practice: 16-week evaluation of clinical effectiveness and serum biomarkers
LFM Ariens1, DS Bakker1, ML Schuttelaar2, JL Thijs1, D Balak1, M Romijn2, T Kouwenhoven3, M Kamsteeg3, B Giovannone1, J Drylewicz4, F van Wijk4, S Nierkens5, J van der Schaft1, M de Bruin-Weller1
1Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Dermatology, University Medical Center Groningen, Groningen, Netherlands, 3Department of Dermatology, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands, 4Laboratory of Translational Immunology, Utrecht, Utrecht, Netherlands, 5U-DAIR, University Medical Center Utrecht, Utrecht, Netherlands

83 In silico modeling of acute irritant-induced inflammation
Georgios Stamatas1, Jalil Bensaci2, Elea Greugny1, Thierry Oddos1
1Johnson & Johnson Sante Beaute France, Issy-les-moulineaux, France
84 A combination of serum biomarkers TARC, IL-22, and sIL-2R accurately predicts disease severity in atopic dermatitis patients treated with cyclosporin A or dupilumab

Judith Thijs¹, Daphne Bakker¹, Julia Drylewicz¹, Lieneke Ariens¹, Jorien van der Schaft¹, Barbara Giovannone¹, Marjolein de Bruin-Weller¹, Femke van Wijk², Stefan Nierkens², Dirk-Jan Hijnen³

¹UMC Utrecht, department of dermatology and allergology, Utrecht, Netherlands; ²UMC Utrecht, Laboratory of Translational Immunology, Utrecht, ³EMC Rotterdam, Department of Dermatology, department of dermatology, Rotterdam, Netherlands

85 GPR119 is a potent novel regulator of human sebocyte biology

Kinga Fanni Tóth¹, Arnold Markovics¹, Dorottya Ádám¹, Zsófia Pénzes¹², Ágnes Angyal¹, József Magi¹, Ágnes Poór³, Ilona Kovács³, Christos C. Zouboulis⁴, Tamás Bird⁵⁶, Attila Oláh¹

¹Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; ²Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; ³Gyula Kenézy University Hospital, University of Debrecen, Debrecen, Hungary; ⁴Departments of Dermatology, Venereology, Allergology and Immunology, Brandenburg Medical School Theodor Fontane, Dessau, Germany; ⁵DE-MTA “Lendület” Cellular Physiology Research Group, Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; ⁶HCEMM Nonprofit Ltd., Szeged, Hungary

86 A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in patients with moderate-to-severe plaque psoriasis

Seth Forman¹, David M. Pariser², Yves Poulin³, Michael S. Vincent⁴, Steven A. Gilbert⁴, Elizabeth M. Kieras¹, Ruolun Qiu¹, Dahong Yu¹, Jocelyne Papacharalambous², Elena Peeva²

¹Forward Clinical Trials, Tampa, United States; ²Eastern Virginia Medical School, Norfolk, United States; ³Centre de Recherche Dermatologique du Québec Métropolitain, Quebec City, Canada; ⁴Pfizer Inc, Cambridge, United States

87 Effect of biopharmaceutical treatment on dendritic cells in psoriasis patients

Aleksandra Petrovic¹, Silje Solberg¹², Lene Sandvik²³, Roland Jonsson¹⁴, Silke Appel¹

¹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway; ²Department of Dermatology, Haukeland University Hospital, Bergen, Norway; ³Department of Clinical Medicine, University of Bergen, Bergen, Norway; ⁴Department of Rheumatology, Haukeland University Hospital, Bergen, Norway
88 Topical DS107 for the treatment of mild-to-moderate Atopic Dermatitis: Results from ADVANTAGE, an 8 week phase 2b randomized, double-blind, vehicle-controlled study

Moayed Hamza1, Mark Lebwoh1, Diamant Thaçi3, Markus Weissbach1, David Coughlan1, Emma Guttman-Yassky2, Jonathan Peter4, John Climax1

1 DS Biopharma, Dublin, Ireland, 2 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA, 3 Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 4 Allergology and Clinical Immunology Division, Department of Medicine, Groote Schuur Hospital, University of Capetown Lung Institute, Cape Town, South Africa

89 Activation of κ-opioid receptor (KOR) suppresses pro-inflammatory response of human epidermal keratinocytes

Dorottya Ádám1, Kinga Fanni Tóth1, Fruzsina Sárkány1, Michael Soeberdt2, Christoph Abels2, Attila Oláh1, Tamás Bíró3,4

1 Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 2 Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany, 3 DE-MTA “Lendület” Cellular Physiology Research Group, Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 4 HCEMM Nonprofit Ltd., Szeged, Hungary

90 Proteomics analysis shows that non-invasive epidermal sampling is a robust diagnostic approach for inflammatory skin diseases

Anna Berekmeri1, Adewonuola Alase1, Tom Macleod3, Philip Laws2, Martin Stacey3, Miriam Wittmann1

1 Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, 2 National Institute of Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, United Kingdom, 3 Faculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom

91 DS107, a novel oral inhibitor of T-cell activation, improves the molecular signature of Atopic Dermatitis patients

Emma Guttman-Yassky2, Ana Brandusa Pavel1, Moayed Hamza1, David Coughlan1, Markus Weissbach1, Diamant Thaçi3, Randall Li2, Yeriel D. Estrada2, John Climax1

1 DS Biopharma, Dublin, Ireland, 2 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA, 3 Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
92 Skin and serum microRNAs in Psoriasis and their usefulness as biomarkers
Hortensia De La Fuente\textsuperscript{1}, Pablo Chicharro\textsuperscript{1}, Pedro Rodríguez\textsuperscript{1}, Ancor Sanz Garcia\textsuperscript{1}, Mar Llamas Velasco\textsuperscript{1}, Danay Cibrian\textsuperscript{1}, Francisco Sanchez-Madrid\textsuperscript{1}, Esteban Daudén\textsuperscript{1}
\textsuperscript{1}Hospital Universitario de La Princesa, Madrid, Spain

93 Experimental and computational analysis of contaminants in skin microbiome research
Claudia Hülpüsch\textsuperscript{1}, Thomas Nussbaumer\textsuperscript{1,2}, Matthias Reiger\textsuperscript{1}, Vera Schwierzeck\textsuperscript{1,2}, Claudia Traidl-Hoffmann\textsuperscript{1,3,4}, Avidan Neumann\textsuperscript{1}
\textsuperscript{1}Chair and Institute of Environmental Medicine, UNIKA-T, Technical University of Munich and Helmholtz Center Munich, Augsburg, Deutschland, \textsuperscript{2}Institute of Network Biology (INET), Helmholtz Center Munich, Munich, Deutschland, \textsuperscript{3}ZIEL - Institute for Food & Health, Technical University of Munich, Freising, Deutschland, \textsuperscript{4}Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland

94 An investigation of the molecular pathogenesis of Generalized Pustular Psoriasis through neutrophil RNAseq
Marta Vergnano\textsuperscript{1}, Marika Catapano\textsuperscript{1}, Jonathan Barker\textsuperscript{1}, Catherine Smith\textsuperscript{1}, Francesca Capon\textsuperscript{1}
\textsuperscript{1}Division of Genetics and Molecular Medicine, King’s College London, London SE1 9RT, UK, London, United Kingdom

95 Risk of anaphylaxis and conjunctivitis with tralokinumab in atopic dermatitis (AD): Analysis of a Phase 2b, randomized, double-blind, placebo-controlled study (NCT02347176)
Andreas Wollenberg\textsuperscript{1}, Emma Guttmann-Yassky\textsuperscript{2}, Mathias Torpet\textsuperscript{3}, Jonathan I Silverberg\textsuperscript{4}
\textsuperscript{1}Department of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany, \textsuperscript{2}Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA, \textsuperscript{3}LEO Pharma A/S, Ballerup, Denmark, \textsuperscript{4}Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, USA

96 Tralokinumab significantly reduces Staphylococcus aureus colonization in adult patients with moderate-to-severe atopic dermatitis (AD): Results from a Phase 2b, randomized, double-blind, placebo-controlled study (NCT02347176)
Emma Guttmann-Yassky\textsuperscript{1}, Jonathan I Silverberg\textsuperscript{2}, Jef Fensholdt\textsuperscript{3}, Kirsten K Lindegaard\textsuperscript{3}, Andreas Wollenberg\textsuperscript{4}
\textsuperscript{1}Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA, \textsuperscript{2}Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, USA, \textsuperscript{3}LEO Pharma A/S, Ballerup, Denmark, \textsuperscript{4}Department of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany
Tralokinumab with topical corticosteroids (TCS) improves health-related quality of life (HRQoL) in adults with moderate-to-severe atopic dermatitis (AD): A Phase 2b, randomized, double-blind, placebo-controlled study
Jonathan I Silverberg1, Nana Kragh2, Emma Guttman-Yassky3, Andreas Wollenberg4
1Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, USA, 2LEO Pharma A/S, Ballerup, Denmark, 3Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA, 4Department of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany

Validation of the Peak Pruritis Numerical Rating Scale (NRS) in Adolescent Moderate-to-severe Atopic Dermatitis Patients for Use in Clinical Trials
Gil Yosipovitch1, Isabelle Guillemin2, Laurent Eckert2, Matthew Reaney3, Lauren Nelson4, Marci Clark5, Nicole Williams5, Ashish Bansal5, Abhijit Gadkari6
1Department of Dermatology and Itch Center Miller School of Medicine U Miami, Florida, United States, 2Sanofi, Lyon, France, 3Sanofi, Guilford, United Kingdom, 4RTI Health Solutions, Research Triangle Park, United States, 5RTI Health Solutions, Ann Arbor, United States, 6Regeneron Pharmaceuticals, Inc., Tarrytown, United States

The cutaneous microbiome changes significantly in the course of allogeneic hematopoietic stem cell transplantation
Nadine Bayer1, Johanna Strobl1, Lukas Hammer1, Alessandra Riva2, Vijaykumar Patra3, David Berry2, Georg Stary1
1Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria, 2Division of Microbial Ecology, University of Vienna, Vienna, Austria, 3Department of Dermatology, Medical University of Graz, Vienna, Austria

Reduced cutaneous CD200R1 signalling exacerbates inflammatory responses in psoriatic skin
Shafqat Jaigirdar1, Holly Linley1, Chris EM Griffiths1, Amy Saunders1
1Lydia Becker Institute of Immunology and Inflammation, University Of Manchester, Manchester, United Kingdom

Selective IL-23 Blockade with Guselkumab (GUS) Neutralizes Th17- and Psoriasis-associated Serum, Cellular, and Transcriptomic Measures More Potently Than Dual IL-12/23 Blockade with Ustekinumab (UST)
Kim Campbell1, Patrick Branigan1, Feifei Yang1, Yanqing Chen1, Yevgeniya Orlovsky1, M. Merle Elloso1, Jacqueline Benson1, Sandra Garcet2, James Krueger2, Katherine Li1
1Janssen Research & Development, LLC, Spring House, United States, 2Center for Clinical and Translational Science, The Rockefeller University, New York, United States
102 **Low-input RNA sequencing reveals survival program of human skin-resident T cells during complete myeloablation**

Johanna Strobl, Ram Vinay-Pandey, Nadine Bayer, Manuel Mayrdorfer, Bärbel Reininger, Lisa Kleißl, Peter Kalhs, Werner Rabitsch, Christoph Bock, Georg Hopfinger, Thomas Krausgruber, Georg Stary

1 Department of Dermatology, Medical University of Vienna, Vienna, Austria; 2Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; 3Center for Molecular Medicine, Vienna, Austria

103 **Cerdulatinib (DMVT-502), a novel, topical dual Janus kinase/spleen tyrosine kinase inhibitor, improves the cellular and molecular cutaneous signature in patients with atopic dermatitis**


1 Dermavant Sciences, Inc., Durham, United States; 2Dermavant Sciences, Inc., Philadelphia, Unites States; 3Immunovant, Inc., Durham, United States; 4Enzyvant, Inc., Durham, United States; 5Icahn School of Medicine at Mount Sinai Medical Center, New York, United States; 6Dermavant Sciences, Inc., New York, United States

104 **Investigation of cerdulatinib (DMVT-502), a dual Janus kinase/spleen tyrosine kinase inhibitor, in a mouse model of vitiligo**

Vincent Azzolino, Kimberly McHale, John E. Harris

1 University of Massachusetts Medical School, Worcester, United States; 2Dermavant Sciences, Inc., Durham, United States

105 **Imputation of KIR Genes in over 80,000 Samples Reveals Previously Unknown Associations with Psoriasis**


1 University of California Los Angeles (UCLA), Los Angeles, United States; 2University of Melbourne, Parkville, Australia; 3Murdoch Childrens Research Institute, Parkville, Australia; 4Kiel University, Kiel, Germany; 5University of Michigan, Ann Arbor, United States; 6University of California San Francisco (UCSF), San Francisco, United States; 7University of Dundee, Dundee, United Kingdom; 8Kaiser Permanente Division of Research, Oakland, United States

106 **Innovative and robust 3D in vitro models to mimic the characteristic features of atopic skin**

Marine Laclaverie, Pauline Rouaud-Tinguely, Laetitia Marchand, David Boudier, Brigitte Closs

1 Silab R&D department, Saint-viance, France
107 Effectiveness of low-dose, low-frequency PUVA treatment and maintenance in early stage (IA-IIA) mycosis fungoides
Pablo Vieyra-Garcia1, Regina Fink-Puches1, Stefanie Porkert2, Roland Lang3, Sophie Pöchlauer4, Gudrun Ratzinger5, Adrian Tanew2, Sylvia Selhofer3, Sator Paul-Gunther4, Angelika Hofer1, Alexandra Gruber-Wackernagel1, Franz Legat1, Patra Vijaykumar1, Franz Quehenberger6, Lorenzo Cerroni1, Rachael Clark7, Peter Wolf1
1Department of Dermatology, Medical University of Graz, Graz, Austria, 2Department of Dermatology, Medical University of Vienna, Vienna, Austria, 3Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, 4Department of Dermatology, Hietzing Hospital, Vienna, Austria, 5Department of Dermatology and Venerology, Medical University of Innsbruck, Innsbruck, Austria, 6Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria, 7Department of Dermatology, Brigham and Women’s Hospital, Harvard University, Boston, United States of America

108 A review of dermatomyositis induced by drugs
Afshin Sharifzadeh1, Mehdi Rashighi1
1Department of Dermatology, University Of Massachusetts Medical School, Worcester, United States

109 Real-world outcomes of secukinumab in psoriasis: A single-center experience in Taiwan
Cheng-han Liu1, Chaw-ning Lee1, Chao-chun Yang1
1Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

110 Clonality assessment in blood and immunotyping of malignant cells to support choice of treatment for erythrodermic CTCL patients, a CD52 success story of precision medicine
Pablo Vieyra-Garcia1, Isabella Perchtaler1, Thomas Graier1, Peter Wolf1
1Medical University of Graz, Graz, Austria
Defective expression of polycystin-1 promotes inflammation and angiogenesis in psoriasis
Antonios N. Gargalionis1, Evangelia Papadavid6, Lina S. Malakou1, Christos Adamopoulos1, Christina Piperi1, Irene Theohari2, Marjan Nokhbehbsaim3, James Deschner4, Georgios Kokkalis5, Penelope Korkolopoulou2, Athanasios G. Papavassiliou1, Efthimia K. Basdra1
1 Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece, 2 First Department of Pathology, Medical School, National and Kapodistrian University of Athens, ‘Laikon’ General Hospital, Athens, Greece, 3 Section of Experimental Dento-Maxillo-Facial Medicine, Center of Dento-Maxillo-Facial Medicine, University of Bonn, Bonn, Germany, 4 Department of Periodontology and Operative Dentistry, University Medical Center of the Johannes Gutenberg University, Mainz, Germany, 5 Second Department of Dermatology, Medical School, National and Kapodistrian University of Athens, ‘Attikon’ General University Hospital, Athens, Greece

Resident T cells trigger disease-associated tissue responses that stratify clinical outcome in human psoriasis
Irène Gallais-Sérézal1, Elena Hoffer1, Stanley Cheuk1, Liv Eidsmo1
1 Karolinska Institutet and New Karolinska Hospital, Stockholm, Sweden

Stimulator of interferon genes (STING) regulates ultraviolet radiation induced suppression of cutaneous immune responses
Mohammad Asif Sherwani1, Kevin Yang, Nabiha Yusuf1
1 University of Alabama at Birmingham, Birmingham, United States

CTLA-4 induces IDO1 enzymatic activity in dermal dendritic cells from UVB-treated skin
Elisa Martini1, Elena Hoffer1, Stanley Cheuk1, Daniel Ketelhuth1, Liv Eidsmo1
1 Karolinska Institutet, Stockholm, Sweden

Culprit drugs induce specific IL-36 overexpression in Acute Generalized Exanthematous Pustulosis
Barbara Meier1, Mark Mellett1, Emmanuel Contassot1, Lars French1, Laurence Feldmeyer2
1 University Hospital Zurich, Zurich, Switzerland, 2 University Hospital Bern, Bern, Switzerland

Development of tools to study functional properties of scarce resident T cells in human skin.
Jaanika Kärner1,2, Borislav Ignatov1,2, Liv Eidsmo1,2
1 Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden, 2 Department of Dermatology, Karolinska University Hospital Solna, Stockholm, Sweden
117 Early Improvement in Pruritus and Reduction in Clinical Signs in a Phase 2a Mechanism of Action Study of Crisaborole in Mild to Moderate Atopic Dermatitis


1Innovaderm Research, Montreal, Canada, 2Pfizer Inc., Groton, USA, 3Pfizer Inc., Collegeville, USA, 4Pfizer Inc., Surrey, UK, 5Icahn School of Medicine at Mount Sinai, New York, USA

118 Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy

Pia Gamradt1, Léo Laoubi1, Audrey Nosbaum1, Virginie Mutez1, Vanina Lenief1, Sophie Grande2, Daniel Redoulès3, Anne-Marie Schmitt4, Jean-François Nicolas1, Marc Vocanson1

1CIRI, International Center for Infectiology Research, Lyon, France, 2Allergology & Clinical Immunology, CH Lyon-Sud, Pierre-Bénite, France, 3Pierre Fabre R&D Dermocosmétique, Toulouse, France, 4Pierre Fabre R&D Pharmaceuticals, Toulouse, France

119 Successful Treatment of Kimura Disease Using Intravenous Immunoglobulin

Malak Altewerki1, Nada Alqadri, Saad Alajlan

1Alfaisal University, Riyadh, Saudi Arabia

120 Massive expansion of drug-specific, clonotypic and polycytotoxic CD8+ T cells in Toxic Epidermal Necrolysis

Axel Patrice Villani1, Aurore Rozieres1, Benoît Bensaid2, Klara Eriksson3, Floriane Fusili1, Audrey Nosbaum1,4, Floriane Albert5, Virginie Mutez1, Tugba Baysal1, Mathilde Tardieu4, Omran Allatif5, Thibault Andrieu5, Denis Jullien2, Catherine Giannoli6, Henri Gruffat1, Marc Pallardy1, Janet Maryanski6, François-Loïc Cosset1, Osami Kanagawa1, Jean-François Nicolas1,4, Daniel Yerly1, Marc Vocanson1

1CIRI, International Center for Infectiology Research, Lyon, France, 2Dermatology department, CH Edouard Herriot, Lyon, France, 3Rheumatology, Immunology and Allergology department, University Hospital, Bern, Switzerland, 4Allergology & Clinical Immunology department, CH Lyon-Sud, Pierre Bénite, France, 5SFR Biosciences, UMS3444/US7, Lyon, France, 6Etablissement Français du Sang, Lyon, France, 7INSERM UMR 996, Châtenay-Mallabry, France, 8Nice Sophia Antipolis University, Nice, France

121 Development of tools to study functional properties of scarce resident T cells in human skin

Borislav Ignatov1,2, Jaanika Karner1,2, Liv Eidsmo1,2

1Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska Institute, Sweden, 2Department of Dermatology, Karolinska University Hospital Solna, Sweden
Unraveling the roles of apocrine sweat glands in Hidradenitis Suppurativa
Catherine Lu
1 New York University Langone Medical Center, New York, United States

New innovative approach combining comparative transcriptomics from three unique psoriasis models to identify predictive PsA biomarkers
William Swindell1, Johann Gudjonsson2, Nicole Ward3
1 Ohio University, Athens, United States, 2 University of Michigan, Ann Arbor, United States, 3 Case Western Reserve University, Cleveland, United States

Inflammasome Signaling and Impaired Vascular Health in Psoriasis
Michael Garshick1, Tessa Barrett1, Todd Wechter3, Sarah Azarchi1, Sanja Jelic2, Stuart Katz1, Jose Scher1, Andrea Neiman1, Judilyn Duculan-Fuentes4, Edward Fisher1, James Krueger4, Jeffrey Berger2
1 New York University Health Langone, New York City, United States, 2 Columbia University Medical Center, New York City, United States of America, 3 Stony Brook University, Stony Brook, United States of America, 4 Rockefeller University, New York City, United States of America

Selective oral JAK3 and TYK2/JAK1 kinase inhibitors both demonstrate significant hair-growth compared to placebo and improvement of hair-associated keratins in patients with moderate-to-severe Alopecia Areata
Emma Guttman-Yassky1, Karen Page2, Ana B Pavel1, Aisleen Diaz1, Yeriel Estrada1, Anindita Banerjee2, Weidong Zhang2, Linda Zhu2, Christopher Banfield2, Lori Cox2, Michael Vincent2, Elena Peeva2
1 Icahn School of Medicine at Mt. Sinai, New York, United States, 2 Pfizer Inc, Cambridge, United States

Macrocystis pyrifera kelp ferment: anti-inflammatory and pro-resolution properties in skin cells
Donald Collins1, Krystle Corallo2, Nevena Karaman-Jurukovska2, Cynthia Hsu2, Dawn Layman2, Nadine Pernodet2
1 Max Huber Research Laboratories, Melville, United States, 2 Estee Lauder Research Laboratories, Melville, United States

Dysbiosis in Obese Individuals Includes Overrepresentation of Corynebacterium, a Known Inflammatory Microbe in the Obese State
Michael Brandwein1, Ariel Katz2, Ron Kohen1-2
1 MYOR, Jerusalem, Israel, 2 Hebrew University of Jerusalem, Jerusalem, Israel
Circulating levels of psoriasis-reared miRNAs and cardiometabolic risk factors in patients with moderate-severe plaque psoriasis

Jesus Gay-Mimbrera1, Macarena Aguilar-Luque1, JL Sanz-Cabanillas1,2, Pedro Carmona1,2, Fran Gómez-García1,2, Beatriz Isla-Tejera1,3, Antonio Velez Garcia-Nieto1,2, Juan Ruano1,2

1 Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Hospital Universitario Reina Sofia/University of Cordoba, Córdoba, Spain, 2 Department of Dermatology, Hospital Universitario Reina Sofia, Córdoba, Spain, 3 Department of Pharmacy, Hospital Universitario Reina Sofia, Córdoba, España

Molecular skin and serum profiles of orphan ichthyoses demonstrate Th17 pathway activation and barrier defect

Helen He1, Kunal Malik1, Thy Nhat Hyunh3, Gary Tran3, Kelly Mueller3, Kristina Doytcheva3, Yael Renert-Yuval4, Tali Czarnowicki1,2, Yeriel Estrada1, Xiangyu Peng1, Hui Xu1, Xiuzhong Zheng2, James Krueger2, Amy Paller3, Emma Guttman-Yassky1,2

1 Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, United States, 2 Laboratory for Investigative Dermatology, Rockefeller University, New York, United States, 3 Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, United States, 4 Department of Dermatology, Hebrew University Medical Center, Jerusalem, Israel

A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis

Ian M Catlett1, Sarah Hu1, Subhashis Banerjee1, Kenneth Gordon2, James G Krueger3

1 Bristol-Myers Squibb, Princeton, United States, 2 Medical College of Wisconsin, Milwaukee, United States, 3 The Rockefeller University, New York, United States

WITHDRAWN

Which characteristics does an optimal animal model for psoriasis need to show?

Amos Gilhar1, Aviad Keren1, Ralf Paus2,3

1 Technion, Haifa, Israel, 2 University of Miami, Miami, U.S.A, 3 University of Manchester, Manchester, U.K

Development of a novel humanized mouse model for atopic dermatitis

Aviad Keren1, Christoph Riehmüller2, Yehuda Ullmann1, Ralf Paus3,4, Amos Gilhar1

1 Technion, Haifa, Israel, 2 Serendip GmbH, Munster, Germany, 3 University of Manchester, Manchester, U.K, 4 University of Miami, Miami, U.S.A
Mouse models of alopecia areata: C3H/HeJ mice versus the humanized AA mouse model
Amos Gilhar\textsuperscript{1}, Aviad Keren\textsuperscript{1}, Ralf Paus\textsuperscript{2,3}
\textsuperscript{1}Skin Research Laboratory, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel, \textsuperscript{2}Department of Dermatology & Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA, \textsuperscript{3}Dermatology Research Centre, University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, UK

Exploiting a human skin platform for analysis of anti-inflammatory compounds
Damon Bevan\textsuperscript{1}, Erica Hawkins\textsuperscript{2}, Jeremy Turner\textsuperscript{3}, Govind Chandra\textsuperscript{2}, Gerhard Saalbach\textsuperscript{2}, Marc Moncrieff\textsuperscript{3}, Cathie Martin\textsuperscript{2}, Jelena Gavrilovic\textsuperscript{1}
\textsuperscript{1}Norwich Skin Platform, School of Biological Sciences, University Of East Anglia, Norwich Research Park, Norwich, United Kingdom, \textsuperscript{2}John Innes Centre, Norwich Research Park, Norwich, UK, \textsuperscript{3}Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich Research Park, Norwich, UK

Molecular Profiling of Acne Vulgaris reveals systemic up-regulation of Th17/Th1 axes even in non-lesional skin
Teresa Song\textsuperscript{1}, Ana B. Pavel\textsuperscript{1}, Ester Del Duca\textsuperscript{1}, Ning Zhang\textsuperscript{1}, Yeriel Estrada\textsuperscript{1}, Brian Kidd\textsuperscript{2}, Joel T. Dudley\textsuperscript{2}, Panayiota Govas\textsuperscript{1}, Emma Guttman-Yassky\textsuperscript{1}
\textsuperscript{1}Department of Dermatology, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, United States, \textsuperscript{2}The Genomic Institute, Icahn School of Medicine at Mount Sinai, New York, United States

Frontal Fibrosing Alopecia tissue profiling exhibits Th1 and JAK-STAT upregulation with diminished expression of stem cell markers
Juan Ruano Ruiz\textsuperscript{1}, Riana D. Sanyal\textsuperscript{2}, Teresa Song\textsuperscript{2}, Ana B. Pavel\textsuperscript{2}, Jesus Gay-Mimbrera\textsuperscript{1}, Robert G. Phelp\textsuperscript{3}, Ning Zhang\textsuperscript{2}, Juan Luis Sanz-Cabanillas\textsuperscript{4}, Randall Li\textsuperscript{2}, Daniella Mikhaylov\textsuperscript{2}, Yeriel Estrada\textsuperscript{2}, Emma Guttman-Yassky\textsuperscript{2}
\textsuperscript{1}Department of Dermatology, IMIBIC/Reina Sofia University Hospital, University of Córdoba, Spain, \textsuperscript{2}Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, United States, \textsuperscript{3}Department of Pathology, Division of Dermatopathology, Icahn School of Medicine at Mount Sinai, New York, United States, \textsuperscript{4}Immune-mediated Inflammatory Skin Diseases Research Group, IMIBIC/Reina Sofia University Hospital, University of Córdoba, Spain

Blood endotyping distinguishes the profile of vitiligo from other inflammatory and autoimmune skin diseases
Tali Czarnowicki\textsuperscript{1,2}, Helen He\textsuperscript{2}, Alexandra Leonard\textsuperscript{1}, Hyun Je Kim\textsuperscript{1}, Naoya Kameyama\textsuperscript{1}, Ana Pavel\textsuperscript{1}, Yeriel Estrada\textsuperscript{1}, Hee Kim\textsuperscript{1}, Margot Chima\textsuperscript{1}, Mark Lebwohl\textsuperscript{1}, James Krueger\textsuperscript{2}, Emma Guttman-Yassky\textsuperscript{1,2}
\textsuperscript{1}Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, United States, \textsuperscript{2}Laboratory for Investigative Dermatology, Rockefeller University, New York, United States
Late-breaking Abstracts per November 26, 2018

LB 1  Urinary squamous cell carcinoma antigen in psoriasis patients: the first pilot study
Jingwen Xue¹, Ziwen Sun²,³, Xiamin Shi⁴, Yun Wang⁵, Suzhen Ji³, Yi Zhao¹
¹Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China, ²Shanghai dermatology Hospital, 20034 Shanghai China, ³Department of Dermatology and Venereology, Peking University First hospital, Beijing 100191, China, ⁴Department of Clinical Laboratory, Peking University First hospital, Beijing 100034, China

LB 2  Epidermal neutrophil recruitment in response to staphylococcus aureus colonization of human skin
Anette Schulz¹, Lisanne de Vor¹,², Long Liang³, Jaanika Kärner³, Markus Ehrström⁴, Fredrik Wermeling³, Liv Eidsmo³, Keira Melican¹
¹Swedish Medical Nanoscience Center, Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden, ²Graduate School of Life Science, Utrecht University, Utrecht, Netherlands, ³Department of Medicine, Karolinska universitetssjukhuset, Stockholm, Sweden, ⁴Department of Molecular Medicine and Surgery, Karolinska universitetssjukhuset, Stockholm, Sweden

LB 3  Efficacy and safety of BI 655130, an anti-interleukin-36 receptor antibody, in patients with a moderate-to-severe generalized pustular psoriasis flare
Hervé Bachelez¹, Siew Eng Choon², Slahedidine Marrakchi³, A David Burden⁴, Tsen-Fang Tsai⁵, Akimichi Morita⁶, Hamida Turki⁷, David B Hall⁸, Chandrasena Pamulapati⁹, Patrick Baum⁹, Steven J Padula⁹, Christian Thoma⁹
¹UMR INSERM U1163, Institut Imagine, Paris, France, ²Clinical School Johor, Monash University Malaysia, Johor Bahru, Malaysia, ³Hedi Chaker University Hospital, Sfax, Tunisia, ⁴Institute of Infection Immunity and Inflammation, University of Glasgow, UK, ⁵National Taiwan University, Taipei, Taiwan, ⁶Nagoya City University, Nagoya, Japan, ⁷Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA, ⁸Boehringer Ingelheim International GmbH, Biberach, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim, Germany

LB 4  Guselkumab demonstrates superior long-term responses to secukinumab at Week48 in the treatment of moderate to severe psoriasis: Results from the ECLIPSE trial
Richard Langley¹, Andrew Blauvelt², April Armstrong³, Shu Li⁴, Ming-Chun Hsu⁴, Susan Flavin⁴, Bruce Randazzo⁵, Kristian Reich⁶
¹Dalhousie University, Halifax, NS, ²Oregon Medical Research Center, Portland, OR, USA, ³Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, Spring House, PA/University of Pennsylvania, Phila, PA, ⁶Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany
Does Psoriasis Treatment Alter the Risk of Comorbidities? 
Examining the Evidence

THURSDAY, DECEMBER 13, 2018
TIME: 11:00 am – 12:30 pm
LOCATION: VIENNA, AUSTRIA
VENUE: AULA DER WISSENSCHAFTEN | ROOM: JESUITENSAAL

Patrick Brunner, MD, MSc
Associate Professor
Department of Dermatology
Medical University of Vienna, Austria

Joel M. Gelfand, MD
Professor of Dermatology and of Epidemiology
Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
United States

Kristian D.J. Reich, MD, PhD
Partner
DERMATOLOGIKUM, Berlin
Contract Researcher
SCIderm Research Institute, Hamburg
Professor
Georg-August-University, Göttingen
Germany

Kilian Eyerich, MD, PhD
Professor
Technical University of Munich
Munich, Germany

ACCREDITATION
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credit (CPD).

Supported by an independent educational sponsorship from Eli Lilly and Company.
Does Psoriasis Treatment Alter the Risk of Comorbidities? 
The Evidence

THURSDAY, DECEMBER 13, 2018
TIME: 11:00 AM – 12:30 PM
LOCATION: VIENNA, AUSTRIA
VENUE: AULA DER WISSENSCHAFTEN | ROOM: JESUITENSAAL

Patrick Brunner, MD, MSc
Associate Professor
Department of Dermatology
Medical University of Vienna, Austria

PANELISTS
Joel M. Gelfand, MD
Professor of Dermatology and of Epidemiology
Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
United States

Kristian D.J. Reich, MD, PhD
Partner
DERMATOLOGIKUM, Berlin
Contract Researcher
SCIderm Research Institute, Hamburg
Professor
Georg-August-University, Göttingen
Germany

Kristian D.J. Reich, MD, PhD
Partner
DERMATOLOGIKUM, Berlin
Contract Researcher
SCIderm Research Institute, Hamburg
Professor
Georg-August-University, Göttingen
Germany

Accreditation
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credit (CPD).
Industry Supported Sessions

Complimentary Non-CME Symposium

THURSDAY, DECEMBER 13, 2018  11.00 – 12.30

Does Psoriasis Treatment Alter the Risk of Comorbidities? Examining the Evidence
Symposium supported by Eli Lilly

Chair: Kilian Eyerich, Munich, Germany

11.00 – 11.10  Psoriasis and Comorbidities: An Overview
Kilian Eyerich, Munich, Germany

11.10 – 11.25  The Role of Cytokines in the Pathogenesis of Psoriasis and Associated Comorbidities
Patrick Brunner, Vienna, Austria

11.25 – 11.45  Does Psoriasis Treatment affect Cardiovascular Disease?
Joel Gelfand, Philadelphia, PA, USA

11.45 – 12.05  Psoriasis and Psyche: What Do We Know?
Kristian Reich, Berlin, Germany

12.05 – 12.25  Panel Discussion and Audience Q&A: Implications for Psoriasis Management
All faculty

12.25 – 12.30  Concluding Remarks and Close
Kilian Eyerich, Munich, Germany
Complimentary Non-CME Symposium

FRIDAY, DECEMBER 14, 2018 08.30 – 09.30

Discover the potential: exploring new frontiers of IL-23 inhibitors
Symposium supported by Janssen

Breakfast available 30 minutes before the symposium.

Chairs: Antonio Costanzo, Milano, Italy & Kilian Eyerich, Munich, Germany

08.30 – 08.35 Welcome and introduction
Antonio Costanzo, Milano, Italy

08.35 – 08.55 Advancing the science of psoriasis: the underlying pathology and the role IL-23
Antonio Costanzo, Milano, Italy

08.55 – 09.15 New horizons in managing psoriasis: individualizing care one patient at a time
Kilian Eyerich, Munich, Germany

09.15 – 09.25 Interactive Q&A session
Antonio Costanzo, Milano, Italy & Kilian Eyerich, Munich, Germany

09.25 – 09.30 Summary and closing
Kilian Eyerich, Munich, Germany
Discover the potential: exploring new frontiers of IL-23 inhibitors

Speakers
Antonio Costanzo
Kilian Eyerich

14 December 2018
08:30–09:30
(breakfast available 30 minutes before the symposium)
Aula der Wissenschaften
Vienna, Austria

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium
Date of preparation: November 2018
PHEM/IMM/0518/0021n
Learning objectives

After this meeting, participants should be able to:

- Explain psoriasis pathogenesis and its relation to the development of novel targeted immune therapies
- Evaluate key learnings from the latest clinical data and consider how these can be utilized to improve the management of patients with psoriasis

Programme

08:30–08:35  Welcome and introduction
Antonio Costanzo

08:35–08:55  Advancing the science of psoriasis: the underlying pathology and the role of IL-23
Antonio Costanzo

08:55–09:15  New horizons in managing psoriasis: individualizing care one patient at a time
Kilian Eyerich

09:15–09:25  Interactive Q&A session
Antonio Costanzo and Kilian Eyerich

09:25–09:30  Summary and closing
Kilian Eyerich
Complimentary Non-CME Symposium

FRIDAY, DECEMBER 14, 2018  12.00 – 13.30

THE GREAT DEBATE: Should the Treatment Paradigm for Mild to Moderate Atopic Dermatitis (AD) Evolve?
Symposium supported by Pfizer

Program and speakers T.B.A.
Lunch will be provided

Following the symposium, attendees will be able to answer:

• Is Subclinical Inflammation Significant in Mild to Moderate AD?
• Is the Treatment Goal Symptom Relief or Long-Term Control for Patients With Mild to Moderate AD?
• Can Existing Prescription Therapies Support Evolving Goals for Patients With Mild to Moderate AD?
Complimentary CME Symposium

SATURDAY, DECEMBER 15, 2018  08.00 – 09.30

Atopic Dermatitis and Beyond: Pathogenic and Therapeutic Advances
This activity is supported by an independent educational grant from Sanofi Genzyme.

Breakfast available 30 minutes before the symposium.

08.00 - 08.10  Introduction
Emma Guttman-Yassky, New York, NY, USA

08.10 - 08.35  Atopic Dermatitis: Emerging as a cytokine-driven disease and novel therapeutic developments
Emma Guttman-Yassky, New York, NY, USA

08.35 - 08.55  Pediatric atopic dermatitis-pathogenic and therapeutic advances and implications for the atopic march
Patrick M. Brunner, Vienna, Austria

08.55 - 09.20  Th2 Inhibition beyond atopic dermatitis
Frank O. Nestle, Boston, MA, USA

09.20 - 09.30  Panel discussion
Emma Guttman-Yassky, New York, NY, USA
Patrick M. Brunner, Vienna, Austria
Frank O. Nestle, Boston, MA, USA
THE GREAT DEBATE:
Should the Treatment Paradigm for Mild to Moderate Atopic Dermatitis (AD) Evolve?

FRIDAY, 14 DECEMBER 2018 | 12:00-13:30
ROOM: JESUITENSAAL (2nd Floor) Lunch will be provided

Following the symposium, attendees will be able to answer:
• Is Subclinical Inflammation Significant in Mild to Moderate AD?
• Is the Treatment Goal Symptom Relief or Long-Term Control for Patients With Mild to Moderate AD?
• Can Existing Prescription Therapies Support Evolving Goals for Patients With Mild to Moderate AD?

Visit us at BOOTH 3

This event is sponsored by Pfizer working in collaboration with the event speakers.

www.pfizer.com
PP-CRI-GLB-0127 November 2018 ©2018 Pfizer Inc. All rights reserved.
Following the symposium, attendees will be able to answer:

- Is Subclinical Inflammation Significant in Mild to Moderate AD?
- Is the Treatment Goal Symptom Relief or Long-Term Control for Patients With Mild to Moderate AD?
- Can Existing Prescription Therapies Support Evolving Goals for Patients With Mild to Moderate AD?

This event is sponsored by Pfizer working in collaboration with the event speakers.

Image supplied with permission by DermNet New Zealand.
Dermavant Sciences is a clinical-stage biopharmaceutical company whose goal is to develop and commercialize innovative therapies for inflammatory skin diseases and medical dermatologic conditions. Our current pipeline consists of five product candidates intended to improve patients' lives by targeting five different conditions with significant unmet medical needs. The patient is at the heart of everything we do.
Sponsors & Exhibitors

Platinum Level Sponsorship

Boehringer Ingelheim

Janssen

Lilly

Pfizer

Sanofi

Genzyme

Regeneron

Gold Level Sponsorship

Silver Level Sponsorship

Celgene

Galderma

AbbVie

Leo

Travel Fellowships

Dermavant

Other Contributors

Eczema Association

Dermira

Novartis
What are the causes of generalized pustular psoriasis and palmoplantar pustulosis?

How does interleukin-36 drive the pathology in pustular psoriasis?

Images courtesy of Waikato District Health Board, 2018. Reprinted with permission of DermNet New Zealand. (Torso and hands)
Why is **pustular psoriasis** considered a **distinct entity** to **psoriasis**?

**ERGEBNISSE**

**die sich**

**PATIENTEN WÜNSCHEN**

---

**PLAQUE PSORIASIS** & **PSORIASIS ARTHRITIS**

**OTEZLA®** – DIE OPTION DIREKT NACH EINER KONVENTIONELLEN SYSTEMTHERAPIE

+ Umfassende und anhaltende Wirksamkeit
+ Überzeugendes Langzeit-Sicherheitsprofil
+ Alltagstauglichkeit

---

Aktuelle Beiträge zur Plaque Psoriasis und Psoriasis Arthritis finden Sie auf [psaundo.at/info](http://psaundo.at/info)

---


---

**Zusammenfassung des Sicherheitsprofils laut Fachinformation:** Die in klinischen Phase-III-Studien am häufigsten berichteten Nebenwirkungen waren Erkrankungen des Gastrointestinaltrakts (GIT) einschließlich Diarrhoe (15,7 %) und Übelkeit (13,9 %). Diese GIT-Nebenwirkungen waren meist leicht bis mäßig ausgeprägt, wobei 0,3 % der Patienten mit Diarrhoe und 0,3 % der Patienten mit Übelkeit über starke Beschwerden berichteten. Diese Nebenwirkungen traten im Allgemeinen innerhalb der ersten 2 Wochen der Behandlung auf und bildeten sich in der Regel innerhalb von 4 Wochen wieder zurück. Zu den weiteren am häufigsten berichteten Nebenwirkungen gehörten Infektionen der oberen Atemwege (9,4 %), Kopfschmerzen (7,9 %) und Spannungskopfschmerzen (7,2 %). Insgesamt wurden die meisten Nebenwirkungen als leicht oder harmlos eingeschätzt. Die häufigsten Nebenwirkungen, die in den ersten 16 Wochen der Behandlung zum Therapieabbruch führten, waren Diarrhoe (1,7 %) und Übelkeit (1,3 %). Die Gesamtrate der schwerwiegendsten Nebenwirkungen war gering und führte nicht zu einer abnormen Ausprägung eines bestimmten Organsystems. Überempfindlichkeitsreaktionen wurden in klinischen Studien mit Apremilast gelegentlich beobachtet. Bitte beachten Sie zusätzlich die jeweils gültige Version der Fachinformation.
Take the opportunity to visit our booth at ISDS 2018 to meet and discuss with our team and explore LEO Pharma’s dedication to dermatology.
Cosentyx® 150 mg Injektionslösung in einem Fertigpen

Cosentyx® 150 mg Injektionslösung in einer Fertigspritze

Qualitative und quantitative Zusammensetzung

Ein Fertigpen enthält 150 mg Secukinumab* in 1 ml.
Eine Fertigspritze enthält 150 mg Secukinumab* in 1 ml.

*Secukinumab ist ein gegen Interleukin 17A gerichteter, rekombinanter, vollständig humaner monoklonaler Antikörper. Secukinumab gehört zur IgG1/Klasse und wird in Ovularkernen des chinesischen Hamsters (CHO-Zellen) produziert.

Liste der sonstigen Bestandteile
Trehalose-Dihydrat
L Histidin
L Histidinhydrochlorid-Monohydrat
L Methionin
Polysorbat 80
Wasser für Injektionszwecke

Anwendungsgebiete

Plaque-Psoriasis
Cosentyx® ist angezeigt für die Behandlung erwachsener Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis, die für eine systemische Therapie in Frage kommen.

Psoriasis-Arthritis (PsA)
Cosentyx® allein oder in Kombination mit Methotrexat (MTX), ist angezeigt für die Behandlung erwachsener Patienten mit aktiver Psoriasis-Arthritis, wenn das Ansprechen auf eine vorhergehende Therapie mit krankheitsmodifizierenden Antirheumatischen Arzneimitteln (DMARDs) unzureichend ist. Cosentyx ist für die Behandlung der aktiven Psoriasis-Arthritis (PsA) bei erwachsenen Patienten, die auf eine vorangegangene DMARD-Therapie unzureichend angesprochen oder diese nicht vertragen haben. Pso-riasis: Otezla® ist indiziert zur Behandlung der mittelschweren bis schweren chronicen Plaque-Psoriasis bei erwachsenen Patienten, die auf eine andere systemische Therapie, wie Ciclosporin oder Methotrexat oder Psoralen in Kombination mit UVA-Licht (PUVA), nicht ansprechen haben oder bei denen eine solche Therapie kontraindiziert ist oder die diese nicht vertragen haben.

Cosentyx® – Für mich die richtige Entscheidung

- Überzeugende Wirksamkeit bei PsO und PsA\(^1\)\(^–\)\(^6\)
- Günstiges Sicherheitsprofil\(^2\),\(^3\),\(^6\)\(^–\)\(^9\)
- Erwiesene Wirkung auch bei Manifestationen der Plaque-Psoriasis an Nägeln, Kopfhaut und palmoplantar\(^7\)\(^–\)\(^9\)

Anhaltende Wirksamkeit über 5 Jahre bei PsO\(^6\)


Glossar: Plaque-Psoriasis (PsO), Psoriasis-Arthritis (PsA).

Novartis Pharma GmbH | Stella-Klein-Loew-Weg 17 | 1020 Wien | www.novartis.at | +43 1 866 57-0 | Datum der Erstellung: 04/2018 | AT1804819894